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The technology described herein is a device based therapy targeting recovery of cardiac 
function in patients with congestive heart failure. This represents a shift in the present 
paradigm wherein available treatment options conservatively target inhibiting disease 
progression, e.g. non-adjustable cardiac support devices and/or alleviating symptoms, 
e.g. blood pumps for circulatory assist.  Specifically, the innovation is a minimally 
invasive device incorporating adjustable passive cardiac support and synchronous active 
cardiac assist – device based technology designed to provide rehabilitative physical 
therapy for the heart muscle, mediating restorative remodeling processes to facilitate 
recovery of cardiac function. CHF affects more than 5.3 million people in the U.S. with 
550,000 new cases diagnosed each year. For 300,000 Americans in end-stage failure, 
transplant is the preferred treatment; however, with less than 3,000 hearts available this 
treatment plan is epidemiologically trivial. The development of a therapeutic option 
targeting recovery of cardiac function would be a substantial advancement in the 
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treatment of heart failure, and consequently a great benefit to the healthcare economy, 
biomedical science, and society as whole.  
 
Device performance was assessed in an acute implantation in an ovine model of acute 
heart failure (esmolol overdose). In the study it was confirmed that the device which was 
designed to be collapsible into a 1 ½” diameter deployment tube and could be deployed 
using minimally invasive procedures. In examining pressure-volume loops, it was 
confirmed that the passive component of the device enabled a leftward shift in the end-
diastolic pressure-volume relationship; important as disease typically shifts this 
relationship to the right. Further, it was verified that the active component of the device 
was capable of restoring stroke work lost in the esmolol induced failure model. Finally, 
the device did not invert the curvature of the heart, did not interfere with normal cardiac 
function, and remained in place through an intrinsic pneumatic attachment and thus did 
not require tethering to the myocardium. The versatile combination of support and assist 
provide the cardiologist with powerful therapeutic options to treat a wide variety of 
patient specific anomalies – with the primary target, rehabilitation of the heart and 
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1. INTRODUCTION: CONGESTIVE HEART FAILURE 
 
Congestive heart failure (CHF) is a major public health issue in the “developed world” 
and an emerging health problem in the “developing world”. CHF affects more than 5.3 
million people in the U.S., with 550,000 new cases diagnosed each year. The associated 
mortality rate is about 40% within 2 years of diagnosis; patients with the most advanced 
stages of disease have a one-year mortality rate that exceeds 50%. Treatment is 
expensive with costs that are escalating. Approximately 20% of hospitalizations are due 
to acute CHF, incurring a health-care system cost of $34.4 billion [1]. Total inpatient and 
outpatient medical costs have been estimated to be in excess of $50 billion per year [2]. 
 
1.1 Progression of Congestive Heart Failure 
 
CHF has a complex etiology and is a progressive disorder thought to be initiated by 
some index cardiac event. Coronary artery disease precipitates approximately 70% of 
CHF cases. Acute myocardial infarction (AMI) due to obstruction of a coronary artery is 
a common initiating event that can ultimately lead to heart failure. The hemodynamic 
and symptomatic states of the patient worsen over time causing further damage despite 
the absence of additional clinically apparent adverse events [3]. 
 
____________ 
This dissertation follows the style of ASME Journal of Medical Devices. 
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One of the major maladaptive changes after a major heart attack or cardiac event is an 
initial decline in pumping capacity of the heart. This leads to the activation of a variety 
of compensatory mechanisms, and subsequently, a phenomenon known as cardiac or left 
ventricular (LV) remodeling (i.e. a geometrical change in the architecture of the left 
ventricle) and aberrant cardiac motion. LV remodeling is a progressive phenomenon 
characterized globally by changes in LV chamber size and shape. There are also 
implications at the cellular level, i.e. ongoing loss of cardiomyocytes, myocyte 
hypertrophy and interstitial fibrosis [4, 5]. LV remodeling dramatically alters the 
mechanical environment, which in turn influences growth and remodeling processes. 
Thus, a positive feedback loop emerges leading to acute dysfunctional cardiac pumping, 
pathologic neurohormonal activation, and the inability of the remodeled LV to respond 
appropriately to compensatory mechanisms. Ultimately, this leads to a stage where the 
aggregate end-organ changes that occur within the cardiomyopathic ventricle progress to 
the point that no amount of neurohormonal stimulation can maintain cardiovascular 
homeostasis. At this point heart failure may progress independent of the neurohormonal 
status. Considering the strong role of LV remodeling in promoting a maladaptive cardiac 
geometry, preventing or reversing remodeling has emerged as an important target in the 







1.2  Pathophysiology of Left Ventricular Remodeling in Heart Disease 
 
As the disease progresses there is a change in the shape of the ventricle from a prolate 
ellipse to a more spherically shaped ventricle [7]. This transformation from elliptical to 
spherical shape and associated functional changes are directly related to future 
deterioration in LV performance and less favorable clinical outcomes in patients with 
heart failure [8-11]. Clinical data provides increasing evidence that LV remodeling can 
contribute to the progression of heart failure by virtue of the de novo mechanical and 
energetic burdens that are created by the physiologically unfavorable changes that occur 
in the remodeled ventricle [12]. As the load on the ventricle at end-diastole contributes 
importantly to the afterload that the ventricle faces at the onset of systole, any dilation of 
the LV will increase the work of the ventricle leading to increased oxygen utilization. 
Apart from the increase in LV end-diastolic volume, LV wall thinning also occurs. Thus 
increase in wall thinning along with the increase in afterload created by LV dilation 
leads to a functional “afterload mismatch” that may further contribute to a decrease in 
forward cardiac output (CO), [13-16]. Moreover, the high end-diastolic wall stress might 
be expected to lead to episodic hypoperfusion of the subendocardium with resultant 
worsening of LV function [17-19], as well as increased oxidative stress, with the 
resultant activation of families of genes that are sensitive to free radical generation (e.g. 




Progressive LV dilation and subsequent remodeling is one of the mechanisms that lead 
to LV wall stress and myocardial stretch [20, 21].  Increased LV wall stress may lead to 
sustained expression of stretch-activated genes (angiotensin II, endothelin and tumor 
necrosis factor) [22-24] and/or stretch activation of hypertrophic signaling pathways as 
stretch triggers myocyte responses both by inducing the release of humoral factors that 
are important in the initiation and maintenance hypertrophy, as well as via the direct 
activation of the relevant signaling pathways [12, 25]. All these changes lead to 
desensitization of the cardiovascular system to normal homeostatic mechanisms.  
 
LV dilation and increased LV sphericity are also sensitive indicators of poor long-term 
clinical outcome [9, 26]. For the sake of simplicity, cardiac wall stress can be related to 
the ratio of the product of pressure in the ventricles and ventricular radius, to the 
ventricular wall thickness [27]. So with LV remodeling and an increase in ventricular 
volumes and a subsequent increase in ventricular radius, a larger force is required from 
each individual myocyte to produce enough pressure in the ventricles, thus wall tension 
is seen as a function of both internal pressure and vessel radius. Also with ventricular 
remodeling, cardiac mass can increase, with associated changes resulting in ventricular 
wall thickness [28]. Any such thickness increase would result from remodeling at the 
cellular/extracellular matrix level by several processes including myocyte hypertrophy, 
cell slippage, and interstitial growth. However, such a wall thickness increase does not 
adequately compensate for the increase in wall stress resulting from cardiac chamber 
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dilation [29] with an increasing metabolic stress. Thus, ventricular remodeling is 
maladaptive, despite any incremental increase in ventricular wall thickness.  
 
1.3 Mitral Regurgitation as a Consequence of Ventricular Remodeling 
 
Increased LV size and chamber sphericity are major determinants of functional mitral 
regurgitation (MR); a condition which depending on its severity can have a major impact 
on reducing LV stroke output which is already impaired in heart failure. As heart failure 
progresses, remodeling of the left ventricle causes the papillary muscles (which support 
the mitral valve leaflets) to stretch out of shape and the valve annulus to enlarge, causing 
the valve to leak leading to mitral regurgitation. Mitral regurgitation (MR) is associated 
with a poor prognosis [30-33]. Recent interest has focused on “functional” or secondary 
MR in which the valve leaflets are anatomically normal but do not fully coapt because of 
annular dilation and restricted leaflet motion secondary to increased left ventricular (LV) 
size and sphericity [34-35]. According to the American Heart Association, around 
95,000 people undergo heart valve surgeries in the US annually. Additionally we 
estimate (i.e., prevalence of CHF minus fraction with diastolic dysfunction, quantity 
halved) that there are nearly 2,000,000 U.S. patients with CHF and mitral regurgitation, 
and we assume that most have not been treated surgically because the risks of the current 
procedure are deemed too high. The high risk of postcardiotomy cardiogenic shock is 
one of the limiting factors of the open heart procedures in patients with moderate to 
advanced heart failure. 
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2. CONCEPTUAL MODELS OF HEART FAILURE 
 
In the last few decades several clinical models have been developed in an attempt to 
describe and investigate the underlying mechanisms associated with the progression of 
heart disease. These include but are not limited to a cardiorenal model, a hemodynamic 
model, and a neurohormonal model. Though these models explain some aspects and/or 
symptoms in heart failure patients; none of these models explain the relentless "disease 
progression" that occurs.  
 
2.1 Summary of Traditional Models of Heart Failure 
 
Initially, CHF was seen as a problem of excessive salt and water retention that was 
caused by abnormalities of renal blood flow also known as the “cardiorenal model” [36]. 
Better quantification of hemodynamic parameters by clinicians led to an understanding 
that heart failure was associated with a reduced cardiac output and excessive peripheral 
vasoconstriction and led to the development of the “cardiocirculatory” or 
“hemodynamic” model [36] for heart failure. Thus, although the cardiorenal models 
provided the rational basis for the use of diuretics to control the volume status of patients 
with heart failure, and the cardiocirculatory model provided the rational basis for the use 
of inotropes and intravenous vasodilators to augment cardiac output, these therapeutic 
strategies have not prevented heart failure from progressing, nor have they led to 
prolonged life for patients with moderate to severe heart failure [36, 37].  
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The advent of ACE (angiotensin-converting enzyme) inhibitors and beta blockers has 
dramatically changed the way in which we conceptualize heart failure. Various studies 
and clinical trials have provided data and have led to both experimental model systems 
and clinical trials which suggest that both types of therapy may prevent the progression 
of pump dysfunction that characterizes the natural history of heart failure and may halt or 
even reverse the progressive cardiac dilatation that occurs as heart failure progresses. 
These observations have led to a point of view that heart failure should be viewed as a 
“neurohormonal model” in which heart failure progresses as a result of the 
overexpression of biologically active molecules that are capable of exerting deleterious 
effects on the heart and circulation [38]. Although the aforementioned models explain 
some of the mechanistic aspects and disease symptoms in the heart failure patients, they 
fail to provide a compelling explanation for the relentless "disease progression" toward 
ultimate total failure. 
 
2.2 The Biomechanical Model of Heart Failure 
 
The “biomechanical model” as developed by Mann and Bristow [12] explains the 
resistance to optimal therapy in end stage patients. There is increasing evidence of an 
important relationship between myocardial systolic dysfunction and cardiac remodeling 
in the development and progression of heart failure. This evidence suggests that heart 
failure can be described via a biomechanical model. A key aspect of the biomechanical 
model is the explanation of the resistance to optimal therapy in end stage patients. One 
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important departure of the biomechanical model from the neurohormonal model is that 
the biomechanical model predicts that
 
at some point heart failure will progress 
independently of the
 
neurohormonal status of the patients. Thus, when the deleterious 
changes in cardiac function and cardiac remodeling are sufficiently advanced, they 
become self-sustaining and hence are capable of driving disease progression 
independently of the neurohormonal status of the patient. This may help to explain, at 
least in part, why conventional neurohormonal strategies lose effectiveness in end-stage 
heart failure [39] as well as why many device-based therapies that concurrently affect 
LV pump performance and LV remodeling (e.g., cardiac resynchronization) are 
beneficial [12], often in ways that extend beyond the therapeutic intent of the design.   
 
Though the biomechanical model provides a new insight into the way the problem is 
approached, it does not obviate the importance of the cardiorenal and hemodynamic 
models, or neurohormonal activation in the onset of heart failure. Rather it extends the 
insights provided by focusing the treatment of heart failure on the downstream biological 
consequences of neurohormonal activation rather than on the neurohormonal activation 
itself. From this perspective, evidence suggests that future therapies should be targeted 
more at alleviating the adverse biological consequences of neurohormonal activation, 





3. MECHANICS AND MECHANOBIOLOGY IN CHF 
 
The heart is essentially a biomechanical pump and the important pillars of biomechanics 
i.e. force (i.e., stress) and motion (i.e., strain) play a fundamental role in the 
mechanobiology and development of physiological and pathological states. The 
understanding of the influence of mechanical stimuli on biological processes such as 
growth and remodeling is at a very early stage and their application in unraveling the 
mechanisms of disease process needs to be explored more innovatively and is crucial to 
understanding cardiovascular diseases and treatments. 
 
It is well established that mechanical stimuli (e.g., stress or strain) are important 
epigenetic factors in cardiovascular development, adaptation, and disease [40-42]. 
Mechanical cues are known to play an important role in cardiogenesis, morphogenesis 
[42], and stem cell fate in general [43]. In the vasculature, it appears that perturbed 
loading conditions heighten the turnover of cells (proliferation and apoptosis) and matrix 
(synthesis and degradation) in altered configurations, thus resulting in altered 
geometries, properties, and biologic function [44]. Just as similar mechanisms appear to 
be operative in hypertension, aneurysms, and micro-gravity induced changes, it is likely 
that they are operative in cardiac disease [45]. Myocytes are very sensitive to 
perturbations in strain and respond with altered gene expression [46, 47]. Cellular and 
subcellular investigations have established that altered hemodynamic loading leads to 
growth and remodeling of myocytes and extra-cellular matrix [48-51].  Characteristics of 
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CHF include but are not limited to loss of myocyte shortening capability [52, 53], 
calcium dysregulation [54, 55], and unspecified myocyte apoptosis [56, 57]. Myofibrillar 
organization [58], sarcomere alignment [59], and cell migration [60] are all known to be 
mediated by mechanical factors. Stem cell differentiation and function are also known to 
be regulated by mechanical signals [43]. And there is precedence of cardiovascular 
therapy based on controlled induction of remodeling processes by strategic manipulation 
of mechanical factors [61]. 
 
Dyskinesis or aberrant motion of the myocardium during contraction is likely important 
in all diseases of the heart that involve remodeling of the myocardium. Abnormal 
cardiac kinematics is often considered as a symptom of heart failure when in actuality it 
may be a primary cause of the aberrant growth and remodeling. Cardiac muscle fiber 
alignment can be highly disorganized in the failing heart and disrupted by fibrosis. The 
afflicted region is highly dyskinetic exhibiting abnormal motion and mechanics [62].  
Clearly, borderzone myocardium is viable [63] yet overloaded to the extent that it is 
dyskinetic, i.e., lengthens when it should shorten. It is likely that overloading leads to 
aberrant remodeling because (see review by Kherani [64]) offloading leads to: 
normalization of genes that regulate calcium handling [65], tumor necrosis factor [66] 
and cytoskeleton proteins [67]; regression of fibrosis and cellular hypertrophy [68, 69], 
and improved in-vitro contractile function [70]. Too much offloading is suspected to 
result in heart atrophy [64]. In treating aberrant strain patterns it is possible that the 
growth and remodeling will stop being abnormal and start being restorative. Eliminating 
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hypokinesis, for example, may reduce apoptosis, enhance myocyte development from 
native stem cells [43], and lead to ventricular recovery. Moreover, reverse remodeling 
has been reported in some patients receiving pump type left ventricular assist device 
(LVAD) implants, suggesting that mechanically induced reverse remodeling is possible 
if the appropriate conditions are established [71]. Herein it is proposed that by 
minimizing or eliminating aberrant strain patterns and strategically manipulating the 
mechanical environment, it is possible that normal growth and remodeling processes can 
be directed toward cardiac restoration and rehabilitation. Just as mechanical stimuli lead 
to adverse remodeling, appropriate mechanical stimuli may lead to recovery.  
 
The role of mechanical therapy for treating heart disease is just beginning to be 
investigated. Given the significant role of stress/strain in cardiovascular disease; there is 
a need for devices designed to mediate the strain field and mechanical environment 





4. PRESENT TREATMENT OPTIONS FOR CHF 
 
There are multiple classes of solutions for treating heart failure: pharmaceuticals, stem 
cells, electrical devices, mechanical devices, and surgical reconstruction. Each of these is 
successful at their target action (i.e., beta-blockade, ACE inhibition, electrical pacing, 
cardiac assist, etc); yet heart failure remains a cause of tremendous morbidity and 
healthcare burden. Pharmacological therapy is improving, yet many patients still reach 
end-stage failure and there are too few donor hearts available. A significant publication 
[72] of the Randomized Evaluation of Mechanical Assistance for the Treatment of CHF 
(REMATCH) trial states: “Patients with mild-to moderate heart failure [73] and, 
recently, some with more severe disease [74] have been shown to benefit from drug 
therapy. Nevertheless, the survival and the quality of life of patients with severe heart 
failure remain limited. Cardiac transplantation is the only treatment that provides 
substantial individual benefit, but with fewer than 3,000 donor hearts available 
worldwide per year, its impact is epidemiologically trivial [75].” To mitigate the 
disparity between the number of available donor hearts and the number of patients in 
need of a heart transplant (estimated at 300,000; [76]), the transplant waiting list has 
stringent guidelines. Consequently, most patients who are in need of a transplant are not 
qualified to be placed on the waiting list. Thus, there is great need for treatment options 





4.1 Device Based Therapies 
 
Current therapies for New York Heart Association (NYHA) Class II-IV patients, such as 
medical management with renin angiotensin/aldosterone system antagonists, beta-
blockers, coronary artery bypass grafting (CABG), mitral valve repair and bi-ventricular 
pacemakers have limitations and none specifically address cardiac remodeling, which is 
a fundamental pathophysiologic mechanism of heart failure [77-81].  
 
Mechanical heart assist devices can be classified into active devices that provide 
pumping energy, and passive devices that modulate the shape of the heart. The active 
devices are subdivided into blood pumps (like the DeBakey, Jarvik, Heart Mate), counter 
pulsation assist devices (aortic balloon pumps), and direct cardiac compression devices 
or DCCDs (Anstadt cup). The passive devices (CorCap, Heartnet, Myosplint, etc.) 
directly interact with the heart to change shape or limit growth.  
 
4.2 Active Circulatory Assist Devices 
 
There are numerous histories of artificial hearts and heart assist devices [4, 82, 83]. We 
focus on direct cardiac compression devices (DCCD) and diastolic support devices. The 
other therapies i.e., drugs, biventricular pacing, stem cell therapies, blood contacting 
assist devices, surgical manipulations, or passive stents and constraints, etc., typically 
off-load the heart and thus only modulate the strain pattern indirectly (e.g., through 
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greater ejection fraction). Only DCCDs can directly induce a particular strain pattern. 
However, prior DCCDs have been developed for enhancing ejection fraction or for ease 
of implantation rather than for strain modulation. All, in fact, induce aberrant strain 
patterns during contraction. The Anstadt cup and Cardio-Support System invert 
curvature in long axis planes yet preserve curvature in the short axis planes. The 
AbioBooster, DCC Patch, Hewson device, and Parravicini device pull on the 
interventricular sulci and push on the freewall such that the curvature will increase at the 
sulci and decrease on the freewalls. The Heart Booster inverts curvature in short axis 
planes, yet preserves curvature in the long axis planes. Since they were not designed to 
eliminate aberrant motions, it should not be surprising that prior DCCDs induce aberrant 
strain patterns. Presently the passive support devices, e.g. CorCap (ACORN 
Cardiovascular, St. Paul, Minnesota), purely work in the area of modulating the wall 
stress, but do not provide any systolic actuation or modulation of strain pattern.  
 
Even though long-term assist enhances survival and quality of life, we can and must do 
better. In particular, some patients will experience signs of recovery (ventricular 
recovery) while mechanical assist is provided (see Rose and Frazier [71] for an 
overview). Combination of drug treatment and mechanical assist is even more promising 
[84]. Ventricular recovery is needed and is possible. Fortunately, many researchers are 
addressing ventricular recovery with different approaches (e.g., surgical, drug, and gene 
therapy, stem cells and/or tissue engineering. It is hypothesized that stress and strain 
pattern modulation plays a central role in myocardial growth, remodeling, and recovery. 
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If pharmacotherapy or traditional assist devices do not eliminate aberrant motion and 
forces (through indirect control of strain via such mechanisms as afterload reduction); 
then a device that does modulate stress and strain is clinically needed. Given that stress 
and strain are an important stimulus of myocardial growth and remodeling there is a 
need for a device eliminates dyskinetic or hypokinetic motions in the heart and 
modulates the wall stress to prevent LV dilation and sphericalization. 
 
4.3 Passive Cardiac Support and Constraint Devices 
 
Progressive LV remodeling is considered to be the one of most fundamental aspects of 
heart failure progression.  At this point, two devices, CorCap (Acorn Cardiovascular) 
and HeartNet (Paracor Surgical Inc.) are in human clinical trials; this highlights the need 
for new technologies targeting LV remodeling with passive ventricular restraint devices. 
The CorCap Cardiac Support Device (CSD) is a mesh device that is implanted around 
the heart to reduce wall stress and the first therapy specifically designed to address LV 
remodeling. CorCap is closest to market today and has established, through preclinical 
and clinical studies, the concept of LV remodeling as a device therapy target. Below are 
some details from CorCap preclinical and clinical studies. 
In a dog model of heart failure, animals that received the CorCap CSD demonstrated a 
significant decrease in left ventricular end diastolic volume (LVEDV, p < 0.05) and an 
increase in left ventricular ejection fraction (LVEF, p < 0.05) [85]. In a dog model of 
heart failure, animals that received the CorCap CSD showed improved cardiomyocyte 
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contraction and relaxation, down-regulation of stretch response proteins, and increased 
affinity of the pump for calcium [86]. In an ovine model of heart failure, the CorCap 
CSD implant maintained or reduced heart size and increased LVEF, fractional 
shortening and peak positive dP/dt [87]. In sheep with heart failure produced by ligation 
of coronary arteries, thus causing only mild dilation, consistent findings of reduced 
ventricular size and improved ventricular function were also reported [88]. 
Early clinical studies have shown that the CSD is safe and associated with improvements 
in LV structure and function and patient symptoms. The CorCap was studied in the 
largest prospective randomized multi-centered trial of a surgical device ever completed. 
From a total of 300 recruited patients, a subgroup of 193 patients were enrolled in the 
mitral valve repair or replacement stratum of the Acorn Clinical Trial; 102 patients were 
randomized to the mitral valve surgery alone group (control) and 91 patients were 
randomized to mitral valve surgery with implantation of the CorCap cardiac support 
device. Patients were followed for a median duration of 22.9 months. The study 
demonstrated both safety and effectiveness of the CorCap in patients with advanced 
heart failure and remodeled ventricles. Patients treated with the CorCap Cardiac Support 
Device had significant reductions in LV end diastolic volume (average difference 18.8 
mL; p = 0.005) and LV end systolic volume (average difference 15.6 mL; p = 0.013) 
compared with the control group. Sphericity index was significantly increased in the 
treatment group (average difference 0.045 units; p = 0.018). These changes were 
maintained over three years of follow-up. The improvements in LV size and shape were 
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observed when the CorCap was implanted concomitantly with mitral value surgery or by 
itself. 
Evidence from studies of cardiomyoplasty, suggest that passive mechanical constraint 
may halt or even reverse remodeling of the dilating heart. Moreover, passive cardiac 
constraint has been shown to reduce cardiac enlargement and functional deterioration. 
Results from studies employing current cardiac support devices (CSD) have shown 
promise and advanced understanding of mediating mechanical factors associated with 
the progression of heart failure. Present CSD, e.g. CorCap and Heart-net, are designed to 
provide mechanical constraint and support of an enlarged myocardium; they are not 
adjustable following implant and are not designed to pro-actively treat the concomitant 
reduction in cardiac output associated with hypertrophy. Moreover, these devices are 
designed to fibrose to the heart surface to stabilize the device-heart interaction. The 
ability to adjust the device following implant provides a proactive means to constrain 
and gradually reduce hypertrophy in the diseased heart. The ability to provide active 
assist ensures cardiac output can be maintained at nominal levels during treatment. 
Collectively, these qualities provide a means for stimulating cardiac remodeling events 
under conditions that are restorative toward full cardiac rehabilitation. 
 
Existing cardiac assist devices do not address the idea that the mechanical environment 
can be pathologic, and thereby provide erroneous signals that in turn stimulate aberrant 
or pathologic remodeling in otherwise healthy tissues. Device based therapies that better 
target the pathologic mechanical environment may stimulate development processes, i.e. 
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growth and remodeling processes that are restorative in nature and thereby ultimately, 





5. CARDIAC RECOVERY AND REHABILITATION: SHIFTING THE 
PARADIGM OF DEVICE BASED THERAPIES FOR CHF 
 
Though scientific journals and undergraduate textbooks offer insurmountable evidence 
that mechanical factors influence growth and remodeling of biologic tissues, one need 
not turn to such literature to be convinced that this is indeed the case.  For thousands of 
years it has been understood that a physical conditioning regimen could be employed to 
increase muscle mass and tone, as well as improve cardiopulmonary efficiency. This 
perception persists as evidenced by modern understanding of the importance of 
maintaining a healthy lifestyle, wherein personal physical fitness has been popularized. 
Thus, to establish cause and effect between mechanical factors and the growth and 
development of biologic tissue one need only to carry an appreciable mass for some 
finite time and evaluate the subsequent improvement in one’s ability to do so. The load 
bearing tissues will remodel, given appropriate nutrition, resulting in an improved 
capacity to bear a load. Note also modern understanding of the importance of physical 
therapy targeting rehabilitation following musculoskeletal injury or surgery. For 
example, following surgical repair in the knee capsule, patients undergo a regimen of 
rehabilitative physical therapy wherein the aim is to restore full range of motion of the 
joint and increase strength in the muscle tissue surrounding the knee. Following such 
therapy, patients are expected to resume a quality of life similar to that maintained prior 
to injury. Generally, it is expected that muscular injuries can be treated via restorative 
medicine wherein complete recovery of the patient is common.  
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Ironically, though it is arguably self-evident that mechanical factors influence the 
growth, development and remodeling of biologic tissues, application of this concept is 
conspicuously sparse in the clinical setting – with the exception of the aforementioned 
“common-sense” approach to musculoskeletal therapy. Evidence that broader 
application is warranted, is easily obtained by those willing to pursue it. One example 
involves the development of autologous vein grafts which can be cultivated by axially 
loading a native vessel in vivo. Typically, a vessel in the leg is targeted. Under 
anomalous strain, the vein remodels, extending in length in an attempt to relieve the 
hyper-stressed condition. After some finite time, a section of the remodeled vessel, now 
of excess length, is excised and deployed as an autologous graft elsewhere in the body 
e.g. in the coronary portion of the arterial tree.    
 
Interestingly, given all of the preceding evidence, mechanical therapies targeting 
recovery and rehabilitation for the myocardium do not exist in the clinical setting and are 
considered innovative in the research setting – in spite of the intuitive nature of the 
therapy. The heart is essentially a muscle not altogether too different from any other 
muscle. Cardiomyocytes are certainly unique, in aggregate they represent a unique 
“form” of muscle tissue, but remain in essence – muscle tissue; a tissue that is in essence 
load-bearing and that readily remodels in response to mechanical loading conditions. 
Athletes condition their myocardiums to pump more efficiently by increasing oxygen 
and nutrient rich blood demand through progressively more demanding workouts. In 
time, the athlete’s heart evolves into a well-toned muscular pump. But what happens 
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when the health of this pump is compromised? Though this organ is essentially a 
biomechanical device comprised of mechanotransducing cells and tissues, the potential 
benefits of mediating mechanical factors is notoriously neglected in therapy. For 
example, in the treatment of patients suffering from CHF, pharmacological therapies, 
circulatory assist therapies, and transplant comprise present therapeutic approaches. 
While transplant is highly effective, the lack of available donor organs renders this 
option epidemiologically ineffective. Pharmacological solutions have proven tenuously 
effective at best as the benefits diminish with time. Assist therapies serve primarily to 
compensate for the loss of mechanical work, but do so without consideration of the 
impact on the already pathologic mechanical environment. The side effects of assist 
devices on mechanically induced growth and remodeling of the myocardium is 
essentially ignored – subverted in favor of effects on cardiac output. Note that 
ventricular assist devices are in fact, mechanical therapies distinguished by their ability 
to increase ejection fraction, i.e. sustain blood flow. Evidence from the application of 
these devices reinforces the idea that mechanical loading mediates growth and 
remodeling of biologic tissue – in this case, the heart muscle. Unfortunately, as these 
devices are not designed to provide physical therapy, or rehabilitation, the remodeling is 






5.1 A Novel Device Based Rehabilitation Therapy for the Treatment of CHF 
 
Herein it is proposed that damaged heart muscle could be rehabilitated by employing 
principles similar to those invoked in theories of musculoskeletal rehabilitation. The 
damaged heart muscle functions in a state of dyskinesis (pathologic motion), wherein 
anomalous strain patterns proliferate inducing aberrant growth and remodeling. Existing 
assist therapies, while improving cardiac throughput, are detrimental in that they 
exacerbate the existing dyskinesis. Herein it is proposed (though not studied) that 
restoration of normal physiologic strain patterns, i.e. normal motion, could induce 
restorative growth and remodeling. It is important to note that a device designed for this 
purpose would, in effect, also provide ventricular assist, and thereby improve cardiac 
throughput – as a natural consequence of restoring normal physiologic motion. Though 
clinical metrics such as “ejection fraction” would be immediately improved, the real 
benefit, the objective, would be rehabilitation of the myocardium. Restorative medicine, 
cardiac therapy that results in the rehabilitation of the heart muscle in a manner similar 
to rehabilitation of other load bearing muscle e.g. quadriceps, would represent a dramatic 
change in the treatment of CHF, wherein patients may, in fact, emerge in a state of 
health indistinguishable from that prior to failure.  
 
Constraint and systematic reduction of an enlarging diseased heart without 
compromising cardiac output or imposing aberrant strain patterns will enable cardiac 
remodeling processes that are rehabilitative and restorative with respect to normal 
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physiologic function. Note that non-adjustable passive CSDs are designed to resist 
chronic dilation of end-diastolic volume, as well as reduce ventricular wall stress and 
myocardial stretch. In best case scenarios, passive CSDs may induce reverse remodeling 
toward normal size and function. The limiting factor in this process is the relative 
geometry of the device as compared to the diseased myocardium. Reverse remodeling 
events occur in response to the variations in the mechanical environment imposed by the 
device. Remodeling is an adaptive behavior, and once equilibrium with the device 
imposed mechanical conditions is achieved restorative remodeling will wane. 
Consequently, in order to achieve full rehabilitation of the myocardium it is important to 
be able to intervene in the remodeling process via an adjustable device wherein the 
mechanical conditions required to sustain restorative remodeling can be maintained until 
normal size, shape, and function are achieved by natural growth and remodeling 
processes. 
 
The device being developed is a minimally-invasive device that is deployed into the 
pericardial space surrounding the heart for the purpose of modulating the mechanics of a 
failing heart via both active assist and passive support to achieve heart recovery by 
guidance of intrinsic growth and remodeling processes. The aim of this technology is to 
provide the mechanical environment necessary for growth and remodeling that is 
restorative in nature and potentially rehabilitative. Hypertrophy of the myocardium is 
characteristic of advanced disease. An important and devastating consequence of 
hypertrophy is the substantial loss of pumping efficiency. The technology described 
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herein would provide a means for guided intervention whereby normal growth and 
remodeling processes are directed toward a gradual reduction in size. Active 
synchronous assist capabilities will maintain critical cardiac performance, e.g. cardiac 
output and stroke work, for managing acute heart failure. Specifically, this is a device 
based technology that will (1) provide adjustable passive cardiac support and constraint 
designed to facilitate the gradual reduction in size of hypertrophied diseased hearts, 
thereby improving pumping efficiency; (2) provide active synchronous cardiac assist 
designed to maintain optimum cardiac performance, i.e. stroke volume, cardiac output, 
ejection fraction, stroke work, etc. and kinematics conducive restorative remodeling 
processes; and (3) be deployable via minimally invasive surgical procedures. 
 
This approach is revolutionary and innovative in three important aspects:  
 
• Combination of active and passive device: The proposed treatment of heart failure 
represents a shift in the paradigm of regenerative medicine, whereby kinematics is 
employed to achieve heart recovery in patients that would otherwise be treated with 
a heart replacement procedure (unlikely given that there are only 2000 hearts 
available per year) or receive no substantive treatment at all. A real need exists 
today for the patient population in Class III & IV heart failure stage who need both 
short term assist restoring cardiac output and hemodynamic stability with a 
transition to medium or long term support of active assist and passive support 
combination therapy. Though different devices exist today with specific indications 
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for medium/long term support, the proposed minimally invasive implantable device 
will be the first device which has a dual component of active assist and passive 
support-applicable for medium to long term assist and support leading to reverse 
remodeling over a period of time.  
 
• Customization of the therapy: The active and the passive modes of the device can be 
optimized depending upon which clinical indication is being treated. The active and 
the passive two component design of the device separately modulate the end-
diastolic (ED) and end-systolic (ES) configurations. The device can be operated in 
multiple modes to be able to separately modulate ED and ES volumes, as both will 
change as the recovery of the patient’s heart progresses. This is also a innovation 
which present passive devices like Acorn’s Corcap and Paracor’s Heartnet do not 
possess. 
 
• Minimally invasive & minimal risk of infection and coagulation: The proposed 
device is a major advancement of heart assist technology that minimizes 
invasiveness, infection, and coagulation and most importantly this device allows 
customization of therapy based on the patients’ response to the treatment strategy. 
Heart replacement is highly invasive and induces great trauma on the patient and 
complications from anti-rejection medication. The present technology incorporates 
design principles conducive to leading edge minimally invasive techniques. The 
implications of developing this technology will likely be far-reaching, extending 
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beyond the proposed application. This technology is an excellent candidate for so 
called combination therapies which combine mechanical, electrical, pharmaceutical, 
and/or stem cell therapies.  
 
5.2 Postcardiotomy Cardiogenic Shock and Mitral Regurgitation 
Postcardiotomy cardiogenic shock (PCCS) is defined as the inability to wean 
successfully off cardiopulmonary bypass (CPB) despite maximal inotropic support and 
intra-aortic balloon pump (IABP) support. The risk of cardiogenic shock can be 
mitigated with the application of mechanical assistance. The most common use of 
mechanical assist is in the postcardiotomy shock setting [89-94]. If hemodynamic 
stability is not achieved, an assist device is considered. Many other cardiac surgical 
procedures have benefited from the use of a ventricular assist device (VAD) for 
postcardiotomy shock [95-97]. Technically challenging procedures, such as the Ross 
Operation and left ventricular remodeling procedures, complications from an acute MI, 
such as ruptured papillary muscle (with acute severe MR) and postinfarction ventricular 
septal defect (VSD), have traditionally been labeled as high-risk surgeries that may 
result in postcardiotomy shock states.  
PCCS results in substantial morbidity and mortality. Despite intra-aortic balloon pump 
and inotropic support, some patients with PCCS continue to have a refractory low 
cardiac output. Treatment includes the use of ventricular assist devices (VAD) to support 
the patient until myocardial recovery occurs sufficiently to support end-organ protection. 
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Despite recent improvements in surgical techniques, anesthesia, CPB, and VAD design, 
operative mortality for this group of patients remains quite high, 50% to 70% in some 
reports. For these patients, more effective ventricular assistance is imperative to prevent 
death.  
Because MR is a frequent complication of the chamber dilation associated with CHF, 
there is a significant number of Americans (we estimate 2,000,000) with CHF who 
would or could benefit greatly from valve repair if the risks of surgery were reduced. 
With regard to post cardiotomy recovery, two types of devices, cardiac assist and cardiac 
support, have been found to be beneficial. Although the leading cardiac support device 
(Acorn’s CorCap) was denied approval by the FDA (Food and Drug Administration), it 
showed significant benefit (see Section B.4, clinical studies) for CHF patients having 
surgery for MR repair. A primary reason for denial of Acorn’s PMA (pre-market 
approval) was that they sought approval for use of CorCap in the general CHF patient 
population—rather than just in patients who are already getting surgery for MR repair. 
For the general patient, FDA considered the risks of surgery to be greater than the 
benefit of CorCap placement. Heart failure management consists of multiple stages 
ranging from postcardiotomy short term assist to medium/long term support towards 
destination therapy or reverse remodeling. The bigger challenge towards successful 
management of heart failure is to design effective therapeutic protocols, as the separation 
between indications for recovery, bridge to transplantation and permanent use becomes 
less distinct. Thus, a simple, easy to implant, minimally-invasive device which can 
provide short term assist at postcardiotomy, and then transition to medium to long term 
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support enabling reverse remodeling could be of significant benefit to the 





6. COMPARISON WITH EXISTING DEVICE BASED THERAPIES 
 
The technology presently being developed will have a significant competitive advantage 
over existing and alternate technologies in the treatment of CHF.  This includes 
advantages over (1) active assist devices (e.g. MYO-VAD), which are non-adjustable, 
and also generally invert the curvature of the heart causing aberrant motion (2) blood-
contacting devices (e.g. Thoratec's HeartMate LVAD) that can cause clotting and do not 
aid in reversing enlargement and (3) cardiac support devices (e.g. ACORN) which are 
non-adjustable and incapable of providing circulatory assist in the event constraint 
compromises cardiac output. The versatility of the device is illustrated in Table 1. 
 
The device described herein is a major advancement of heart assist technology that 
minimizes invasiveness, infection, and coagulation. Heart replacement is highly invasive 
and induces great trauma on the patient and complications from anti-rejection 
medication. Current, blood-contacting assist technologies are greater risk for blood 
trauma, clotting activation, and sepsis. Blood-contacting assist technologies cannot be 
started and stopped because of clot formation. The proposed technology is an excellent 
candidate for combination therapies which combine mechanical, electrical, 
pharmaceutical, and/or stem cell therapies. Stem cells will benefit from improved 
mechanical stimuli. Prior devices in the class of direct cardiac compression devices 
(such as the Anstadt cup and cardiac support system) are more invasive and induce 




TABLE 1: Device Comparison. In this comparison the versatility of the device being 
developed herein is evident. More importantly, note that the therapeutic target of this 
device is to stimulate growth and remodeling processes that are potentially restorative 




Counter-Pulsation Devices: IABP 
 
Bridge to Recovery – Short Term Hemodynamic 
Support: 
POST-CARDIOTOMY 
Left Ventricular Assist Devices 
(LVAD) 
 
Bridge to Transplant & Destination Therapy – Short, 
Medium, Long Term Assist: ASSIST 
Cardiac Support Devices 
 
Long Term Reduction of Wall Stress: SUPPORT 
(CorCap, Heartnet) 
Device Under Development 
(Combination of Active Assist 
and Passive Support) 
 
Short to Medium Term: 
POST-CARDIOTOMY + ASSIST + SUPPORT 
Maintain Cardiac Output, Increase Stroke Work, 
Modulate End Diastolic and End Systolic Volume 




pull on others). As will be discussed later, the proposed technology enhances without 
inhibiting normal cardiac motion. 
 
6.1 Advantage over Intra-Aortic Balloon Pumps 
 
Intra-aortic balloon pumps, or counterpulsation assist devices, are simple technologies 
inserted percutaneously provide active circulatory assist. These devices are blood 
contacting and therefore bring the associated risks. Moreover, they have a limited ability 
to modulate heart motion and the end-diastolic (ED) and end-systolic (ES) 
configurations. They add motion to the heart by sucking on the vasculature or deflating 
during the heart’s systolic contraction. The rebound of the arteries and circulatory 
demands, however, limit the ability of aortic balloon pumps to decrease the transmural 
pressure felt by the heart wall. Arterial pressure must remain a significant fraction of 
mean arterial pressure to maintain organ perfusion. In contrast, this device affects the 
transmural pressure gradient by raising the external pressure rather than lowering the 
internal blood pressure. 
 
6.2 Advantage over Left Ventricular Assist Devices 
 
For the left ventricular assist devices, there are multiple challenges in surgery, device 
operation and postoperative care due to the infection and coagulation risks associated 
with devices that touch blood. But over the last decade there have been supportive data 
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towards destination therapy, it is exciting that some patients in end-stage failure 
recovered completely when given a mechanical assist device while on the transplant 
waiting list. This demonstrates that reverse remodeling and heart recovery are possible. 
The present technology is designed to make it possible in every patient with heart failure 
and is a great enhancement over the blood pumps because it is implanted in a minimally 
invasive fashion, there is no sewing to vessels or the heart, no contact with blood, and 
there is direct control of mechanical factors (ED configuration and ES configuration) 
that are likely to be most important for recovery. Thus this technology is a heart assist 
technology than circulatory assist technology. 
 
6.3 Advantage over Present Cardiac Support Devices 
 
Of the passive ventricular restraints in clinical trials are the CorCap device and Paracor’s 
Heartnet. The CorCap is the leading device with a positive record of animal studies, 
clinical studies, and device sales in Europe. Their regulatory approval in the US has been 
difficult presently conducting a 50 patient confirmatory trial for PMA submission, but 
they are the first such device in this class to be near approval. The CorCap can be 
implanted in a minimally invasive fashion, but it is limited in its ability to restore the 
heart to normal, as it is not adjustable. Once inserted, it can limit the heart enlargement, 
but its size cannot be adjusted to continually reduce the ED configuration. To be most 
effective, the CorCap needs to be implanted prior to end-stage failure to limit the 
growth. Deciding which patients need device intervention and which patients will 
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recover on their own is difficult to determine in the early stages of failure. With the 
device described herein, intervention can be accomplished after the development of end-
stage failure because ED configuration can be continuously adjusted. In addition, passive 
devices have limited ability to modulate heart motion because they cannot supply 
pumping power. For example, the CorCap cannot be undersized too much because it 
may limit heart filling and muscle stretch to the point that muscle contraction is too weak 
(i.e., an already shortened muscle cannot shorten much more). With our technology, we 
can supply systolic assist to normalize ejection while reducing the ED configuration. The 
device is not designed to fibrose to the myocardium thus allowing future intervention 





7.  DEVELOPMENT OF A DEVICE THAT PROVIDES ADJUSTABLE 
CARDIAC SUPPORT AND ACTIVE SYNCHRONOUS ASSIST 
 
One of the major maladaptive changes after a major heart attack or cardiac event is an 
initial decline in pumping capacity of the heart leading to activation of variety of 
compensatory mechanisms, and subsequently a phenomenon known as cardiac or left 
ventricular remodeling, i.e. a geometrical change in the architecture of the left ventricle. 
Evidence suggests that mechanical factors are critical, and to control two important 
mechanical parameters, cardiac size and cardiac output.  
 
7.1 Device Actions and Features 
 
Given the prominent role of geometric and mechanical factors in driving the remodeling 
associated with disease progression, an implantable device has been designed to directly 
modulate heart size and motion; so to investigate the effectiveness of mechanical therapy 
to guide reverse-remodeling. Pump type LVAD implants have lead to reverse 
remodeling [71]. Yet, these devices do not modulate heart size and motion directly, 
rather they communicate with heart indirectly via contact with the blood. The device of 
this study, in contrast, surrounds the heart, contacts the epicardial surface of the heart, 
and thus acts on the heart directly, without blood contact. The following two modes of 
operation or device mediated actions (A1, A2) were sought and assessed in an acute 
ovine study:  
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A1) adjustable cardiac support or passive constraint to reduce heart size and  
A2) synchronous active assist to increase heart motion or stroke volume when it has 
depressed motion.  
Moreover, to enable our research goals of testing the effectiveness of the above actions 
to reverse-remodel the heart, we sought and assessed the following three inactions or 
device features (F1,F2,F3):  
F1) does not impede heart function when it is inactive and  
F2) does not invert heart curvature (nor induce similar, abnormal motions) when it is 
activated 
F3) does not dislodge, extrude or expel the heart when it is activated 
These features are necessary for chronic experiments to assess heart remodeling—i.e., 
the next phase of studies. 
 
There is a recent report of a device capable of adjustable cardiac support [98], and there 
are reports of a direct cardiac compression device [99] for providing synchronous active 
assist. Nevertheless, there are no known implantable devices that provide actions A1-A2, 







7.2 Device Construction  
 
The device implanted in this acute, ovine study had six identical chambers composed of 
a nitrile, airtight bladder surrounded by a nylon mesh to constrain bladder expansion and 
to attach adjacent bladders together via 1/8” width stitches of braided nylon thread. The 
device is shown in Figure 1, as placed on the heart and viewed through a sternotomy. 
Each chamber had an identical helical orientation, but shifted 60 degrees so to form a 
complete circumference and form a cup-shaped structure. Polyurethane tubing (0.25” d) 
was employed as the conduit for fluid transport to and from the bladders. The end of the 
tubing within the bladders was spiral cut to prevent the nitrile film from collapsing onto 
to the tube end during the diastolic phase of assist when vacuum was applied to remove 
air in the chambers. The other tube ends were coalesced together into one driveline 
(0.375” d). Although separate in construction, tubing connections made the six-chambers 
contiguous with the same pressure source. The chambers were also attached to a nitinol 
scaffold which provided structural stability and served as a reference electrode for 
acquisition of the electrocardiogram (ECG) signal used to trigger the device. The sense 
electrode was sewn to the heart apex. This epicardial electrode configuration provided an 







FIGURE 1: Dual Function Device. This device consisted of chambers 
which were filled with air to provide support or assist. In support mode a 
static pressure was applied. In assist mode, air was shuttled into the 
chambers during systole, and removed by vacuum during diastole. The 









7.3 Device Control and Monitoring 
 
The ECG was routed to a BNC-2110 connector block which in turn was connected to a 
USB-6251 DAQ Board (National Instruments Corporation, Austin TX). A custom 
LabView (National Instruments Corporation, Austin TX) VI was developed and used to 
monitor device pressure, acquire the ECG, and trigger the device. The front panel user 
interface is shown in Figures 2. The schematic is given in Figure 3. The ECG signal 
from the device is routed to a virtual low pass filter. A threshold algorithm then triggers 
off of the R-wave of the ECG. The program provides independent control of device 
pressurization and evacuation gate times. The trigger activates two virtual gates, one for 
the pressure signal; the other for the vacuum signal. The gate times can be adjusted as 
necessary to provide the desired magnitude of assist or to function as a percentage of the 
corrected QT interval at some fixed magnitude of assist. The device pressure was 
obtained with a Millar pressure catheter transducer (Millar Instruments Inc., Houston, 
TX) placed within one of the device chambers.  
 
The device pressure is adjusted using a custom pneumatic system (Figure 4). Two 
reservoirs are employed. One reservoir is connected to a constant pressure source; the 
other reservoir is connected to a constant vacuum source. A T-fitting is used to couple 
the two sources to the device lines. Solenoid valves determine whether the pressure line 
is sent to the device or alternatively the vacuum. As a precaution the vacuum solenoid 
valve is open in the default state and the pressure solenoid valve is closed in the default 
state. When a trigger is generated a voltage is output to a custom built solid state relay 
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system that activates the appropriate solenoid valves (Figure 5). Thus, the gate times can 










FIGURE 2: Control and Monitoring User Interface. The main display 
of the custom LabView application provides real-time monitoring of the 









FIGURE 3: Schematic of the LabView Application. A custom 
LabView application was developed to control and monitor the device. 
The ECG signal from the device is routed to a low pass filter. A threshold 
algorithm then triggers off of the R-wave. This activates two gates, one 
for pressure signal; the other for the vacuum signal. The gate times can be 
adjusted as necessary to provide the desired magnitude of assist or to 
function as a percentage of the corrected QT interval at some fixed 

















FIGURE 4: Pneumatic System Schematic. This schematic illustrates 
how fluid (air) is transported to and from the device. The device is 
connected to continuous pressure and vacuum sources. Independently 
controlled solenoid valves determine which source is actually applied to 
the device at a given time. The solenoid valves are activated by signals 
generated by the LabView application and routed through a custom solid 













FIGURE 5: Solid State Relay System Schematic. This schematic of the 
custom relay system illustrates how the AC source is routed to the 
appropriate solenoid valve using solid state relays. Lamp 1 simply 
indicates the AC is present at the relays. Lamps 2 and 3 indicate the AC 
source is being routed to switches S4 and S5. This provides a means to 
verify appropriate triggering before actually activating the device via 







8. ASSESSMENT OF AN IMPLANTABLE DEVICE THAT PROVIDES 
ADJUSTABLE CARDIAC SUPPORT AND ACTIVE SYNCHRONOUS ASSIST 
IN AN ACUTE HEART FAILURE MODEL 
 
8.1 Delivery and Assessment of Action A1 
 
Adjustable cardiac support or passive constraint was accomplished by applying a static 
pressure on the driver end of the device driveline. Although we applied a constant or 
fixed pressure, this action is termed adjustable cardiac support because the pressure or 
amount of support can be adjusted post-implantation. We applied two separate, static 
pressures: 1) open to atmospheric pressure, and 2) 10cmH2O (or 7.5mmHg) above 
atmospheric pressure. Device pressure was monitored via the LabView setup; and 
although the pressure was held static at the driver end of the driveline, the pressure in the 
device chambers varied with heart contraction and relaxation. With caval occlusion, the 
end diastolic pressure-volume relationship (EDPVR) for both of the above states was 
determined and then compared to assess the effectiveness of action A1 to shift the 
EDPVR upward or leftward (i.e., toward a smaller heart size). 
 
8.2 Delivery and Assessment of Action A2 
 
Synchronous active assist was accomplished by oscillating the driving pressure of the 
device in synchrony with heart contraction. The LabView program detected the ECG 
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trigger and sent a line voltage signal to a custom designed relay system which shut off 
the solenoid valve to the vacuum pump and opened the solenoid valve to a pressure tank 
regulated to about 1,400 mmHg (approx. 20 psi). After a user specified delay, the 
LabView program cut off the voltage to the solenoid valve to the pressure tank. The 
appropriate delay was determined by starting at a zero and increasing it by a few 
milliseconds after a few cardiac cycles, until the systolic pressure in the device reached 
the desired amount. The amount of time that the pressure tank valve was open was 
significantly less than the length of systole. For example, a few milliseconds of a 1,400 
mmHg pulse at the driver end became, at the device end, a pulse of 30 mmHg that lasted 
for hundreds of milliseconds. After a user specified delay (that was obtained from 
measuring the QT interval on the ECG), the LabView program opened the solenoid 
valve to the vacuum pump. Hence, during systole the vacuum line was closed and the 
line to the pressure tank was opened briefly at the start of systole, filling the device with 
air and thereby applying direct cardiac compression. After a QT delay from the R 
trigger, the vacuum line was opened and the air in the device was evacuated during 
diastole—allowing the heart to fill. To assess the ability of the device to provide 
synchronous cardiac assist for a failing heart, we applied 0 mmHg, 30 mmHg, and 60 
mmHg of systolic assist for two cardiac states: 1) normal or baseline contractility, and 2) 
low contractility or esmolol induced, acute heart failure. For the normal cardiac state an 
active assist of 30mmHg was applied for approximately 5-10 cardiac cycles, after which 
the active assist was shut off for approximately 5-10 cardiac cycles. The same procedure 
was used for the esmolol induced failure state, first with an active assist of 30mmHg and 
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subsequently with an active assist of 60mmHg. PV (pressure-volume) loop analysis was 
used to assess cardiac function during the varying amounts of assist. 
 
8.3 Design and Assessment of F1  
 
The device was made of thin-film bladders, fabric like material, and wires that formed 
an open frame so that it was collapsible when depressurized. The design constraint of 
collapsibility when depressurized was sought so that the device itself did not impede 
cardiac function. To assess this feature, PV loop analysis was done prior to implantation 
(prior to opening the chest) and after implantation (after chest closed). Pre-implant and 
post-implant cardiac functions were subsequently compared. 
 
8.4 Design and Assessment of F2 
 
The outer half of the device chambers formed a continuous, inextensible outer shell of 
nylon whereas the inner half was in direct contact with the heart surface rather than fully 
distended. Consequently, the device was designed to apply uniform pressure to the entire 
epicardial heart surface, as uniform pressure was likely to preserve cardiac curvature—
i.e., it was unlikely to invert the ventricular wall or cause similar aberrant motions. To 
assess the heart shape during device activation, the heart silhouette was observed in 
fluoroscopy videos taken during maximal device activation. The air-heart interface was 
easily identified with x-ray imaging. 
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8.5 Design and Assessment of F3 
 
The chambers of the device were tapered with minimal space near the apex and maximal 
space near the base. Consequently, when the device was activated it took on a cup-like 
shape as opposed to a ball-like shape—the latter being the expected shape for an inflated 
object that does not have chamber partitions. The advantage of a cup-like activated 
shape is that the heart is likely to be retained in the device rather than expelled from the 
device. This is so because there is no free air in the chest to fill the space between an 
expelled heart and the cup cavity. Rather, the heart and device were expected to be 
pneumatically coupled and coaxially fixed without the need of suturing to the heart. To 
assess this feature, the motion of the heart silhouette relative to the wire frame on the 
device was observed in fluoroscopy videos.  
 
8.6 Surgical Procedure  
 
The care and use of the sheep in this acute implant study and terminal procedure was 
conducted at the Texas A&M University College of Veterinary Medicine in accordance 
with an active animal use protocol approved by the Institutional Animal Care and Use 
Committee of the Texas A&M University System. Adult sheep, which weighed 
approximately 70 kg, were premedicated with an anti-anxiety drug (Xylazine 0.075 
mg/lb) and an anticholinergic (glycopyrrolate 0.01 mg/kg).  Both drugs were given 
intramuscularly.  After sedation a 16 g catheter was placed in the left jugular vein and 
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anesthesia was induced with ketamine (4.4 mg/kg) and diazepam (0.11 mg/g) mixed 
together and given intravenously (IV) to effect. After induction and endotracheal 
intubation, the animal was maintained on inhalant anesthesia using a combination of 
isoflurane in oxygen.  The animal was clipped and prepped for a sternotomy procedure, 
The 16g jugular catheter was replaced with an 8 French quad-lumen catheter to allow 
multiple IV access, and an orogastric tube was placed to prevent bloating.  An arterial 
catheter was placed in the left dorsal pedal artery to allow for direct blood pressure 
monitoring.  The animal was placed in dorsal recumbency for the remainder of the study.  
Intraoperative IV fluids and mechanical ventilation were initiated.  Using a Power Lab 
physiological monitoring unit; heart rate, blood pressure, central venous pressure, 
oxygen saturation, ECG, and respirations were monitored throughout the procedure.  A 
lidocaine CRI (constant rate of infusion) was started to prevent arrhythmias and 
buprenorphine (0.02-0.05 mg/kg) was administered for pain. A Millar PV Catheter was 
placed through a left carotid artery cut-down and positioned by use of fluoroscopy. A 
sternotomy was performed and the device was placed over the heart apex. The xiphoid 
process was removed, and the device drivelines and chest tube were routed caudal to the 
sternum. The sternum was closed with wire and the fascia was closed tightly with suture 







8.7 Data Acquisition 
 
Using data acquired via the PV catheter, and the accompanying PVAN software (Millar 
Instruments Inc., Houston TX), cardiac function was evaluated. Pressure-volume (PV) 
relationships were determined for three cardiac states: normal, vena cava occlusion, and 
esmolol induced failure. Measures of heart rate (HR), maximum pressure (Pmax), 
minimum pressure (Pmin), maximum volume (Vmax), minimum volume (Vmin), end-
diastolic pressure (Ped), end-diastolic volume (Ved), end- systolic pressure (Pes), end-
systolic volume (Ves), stroke volume (SV), ejection fraction (EF), cardiac output (CO), 
and stroke work (SW) were obtained. The aforementioned values were calculated for 
each PV loop acquired. A minimum of six loops were acquired for each case. Mean 
values and standard deviations were calculated for each case using the PVAN software 
package. These values were then used to determine statistical significance via a t-test 
with p=0.05. To assess diastolic mechanics, the end diastolic pressure-volume 
relationship (EDPVR) was measured by use of a balloon catheter inflated in the caudal 
cava to reduce the pre-load on the heart. To model acute heart failure, an overdose of 
esmolol was administered. This included four boluses of 33mg each for a volumetric 
sub-total of 13.2ml (0.5-1.0mg/kg), and a constant rate of infusion (CRI) of 0.5-2.0 
mg/kg/min for a volumetric sub-total of 15.2ml, and thus a total volume of 28.4ml 







Action A1: Adjustable Cardiac Support or Passive Constraint to Reduce Heart Size 
 
To assess the passive assist capabilities a balloon catheter was inflated in the vena cava 
to vary the preload. Figure 6A shows the PV loops during onset of caval occlusion with 
device driveline open to atmosphere, and lower-left panel shows the PV loops during 
onset of caval occlusion with the device driveline held at 7.5mmHg. The comparison of 
the EDPVR for the 0mmHg versus 7.5mmHg cases is presented in Figure 6B and shows 
that the EDPVR shifted upward with the 7.5mmHg passive support. This upward shift in 
the EDPVR indicates a decrease in the size of the left ventricle relative to filling 






FIGURE 6A: PV Loops - Vena Cava Occlusion. PV loops acquired in 
the left ventricle during vena cava occlusion with a passive constraint of 
0mmHg. (Left Bottom) PV loops of left ventricle during vena cava 






FIGURE 6B: Shifting the EDPVR with Passive Support. Plots of the 
end-diastolic pressure-volume relationships with and without poassive 
support, during gradual reduction of pre-load accomplished via vena cava 
occlusion with a balloon catheter.   
EDPVR Passive Constraint



























Action A2: Synchronous Active Assist to Increase Heart Motion or Stroke Volume  
 
High dose esmolol infusion reduced SV by 39%, EF by 39%, CO by 42% and SW by 
52% (Figures 7A and 7B). Application of 30mmHg active assist provided substantial 
restoration of cardiac performance as EF, CO, and SW increased significantly by 27%, 
33% and 62%, respectively (p=0.05). Stroke volume is determined by the change in 
volume between the vertical isovolumic segments. For normal contractility, stroke 
volume increased by approximately 11% when the active assist was applied; in the 
esmolol induced failure model, stroke volume increased by approximately 35%. 
Application of 60mmHg active assist resulted in significant increases in SV, EF, and CO 
of 49%, 44%, and 49%, respectively (p=0.05). Increase in SW was dramatic, over 85% 
as compared with the esmolol baseline (Figure 8A). Note that the levels of CO and SW 
achieved with 60mmHg assist were similar to the healthy baseline measures, i.e. 







FIGURE 7A: Esmolol Induced Failure – 30mmHg Assist. Pressure-
Volume loops of the transition from 30mmHg assist to “no assist” in the 
esmolol induced failure model. Here it is evident that assist significantly 






FIGURE 7B: Esmolol Model CO and SW – 30mmHg Assist. 
Comparison of Healthy Baseline, Esmolol Pre-Assist, and Esmolol with 
30mmHg Assist in the esmolol induced failure model. Note that assist 
resulted in significant increases in SW and CO, though levels remained 





FIGURE 8A: Esmolol Induced Failure – 60mmHg Assist. Pressure-
volume loop plots from 60mmHg assist of the esmolol model and the 




FIGURE 8B: Esmolol Model CO and SW – 60mmHg Assist. In this 
comparison of SW and CO levels, it is evident that 60mmHg Assist 
provides significant gains in the esmolol failure model, achieving 
performance levels that were statistically similar to those observed in the 
healthy model.  
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Feature F1: The Device Does Not Impede Heart Function When It Is Inactive 
 
PV loops obtained pre- and post-deployment are shown in Figure 9.  SV, EF, CO, and 
SW were statistically similar pre- and post-deployment. CVP (central venous pressure), 
wedge pressure, and AoP (aortic pressure) were also unaffected by device placement. 
Thus, sternotomy, device placement, and closing the chest did not have a significant 
impact on cardiac function. Although it is of no therapeutic value, it is scientifically 
relevant to measure the cardiovascular response to synchronous active assist on a 
normal, healthy heart. Prior to esmolol infusion to induce heart failure, i.e. in the normal 
contractility state, activation of the device during systole (with 30 mmHg of assist 
pressure)   SW increased over 30% (p=0.05). Significant increases in CO (13%), SV 









FIGURE 9: PV Loops Pre- and Post- Deployment. Note that the 
deployment of the device had no significant effects on cardiac function 









FIGURE 10: Assisting the Healthy Heart. Application of 30mmHg 
active assist to a healthy heart. Note that though SV, EF, CO, and SW 




Feature F2: The Device Does Not Invert Heart Curvature When Activated 
 
Inspection of images obtained via fluoroscopy demonstrates that the device does not 
invert the curvature of the heart when activated. Images were acquired continuously at a 
rate of 15 frames per second over several cardiac cycles. Figure 11 displays fluoroscopic 
images acquired during end-diastole (ED) and end-systole (ES). During systole the 
device is maximally loaded with air that is easily discernible in the images; and 
consequently, the free wall is also apparent. Although the size is reduced from ED to ES, 
the heart shape remained the same in the images—i.e., no curvature inversion or gross 
changes in cardiac shape during systolic activation.  
 
Feature F3: The Device Does Not Dislodge, Extrude or Expel the Heart When Activated 
 
Fluoroscopic imaging was used to verify the proper placement and motion of the heart 
and device. The heart remained in the device throughout the study. Figure 11 provides 
images acquired during systole and diastole. These images affirm proper device 





FIGURE 11: Flouroscopic Imaging of Active Assist. Left – diastole, 
fluid from the device is evacuated. Right – systole, the device is 
maximally filled. Note the free wall is not inverted during maximum 






This investigation was motivated by the premise that mechanical stimuli are critical 
factors for guiding the growth, remodeling, and maintenance of mechanical organs. It is 
common understanding that physical therapy is essential to recovery from injury in the 
musculoskeletal system. In this sense it is well understood that mechanical stimuli are 
critical for proper function of a mechanical organ system. Cardiogenesis is known to be 
guided by mechanical factors. The role of mechanical factors in morphogenesis has also 
been well documented. Patwari and Lee [42] provide a review of this related to the 
cardiovascular system in particular. At the cellular level, myofibrillar organization [58], 
sarcomere alignment [59], and cell migration [60] are all known to be mediated by 
mechanical factors. Mechanical factors are also known to play an important role in the 
behavior of stem cells, suggesting that understanding and control of the mechanical 
environment may be critical to the realization of the potential for stem cell therapies 
[43].  The device described herein is capable of manipulating important mechanical 
factors that may ultimately influence cardiac performance, growth and remodeling 
processes, and regenerative therapies. It is proposed that a device such as that reported 
here may advance investigations of therapeutic options that target cardiac rehabilitation, 
restoration, and/or regeneration. 
 
Considering the strong role of LV remodeling in promoting a maladaptive cardiac 
geometry, preventing or reversing remodeling has emerged as important target in the 
64 
 
treatment of CHF [6]. While there is strong evidence that Cardiac Support Devices 
(CSD) inhibit enlargement, evidence suggesting restorative or rehabilitative remodeling 
is mostly missing and limited to case reports of “reverse remodeling” following 
treatment of an underlying disease (e.g., valve defect or metabolic disease) or after 
placement of a left ventricular assist device in patients awaiting transplant. Nevertheless, 
contractile proteins are in a constant state of flux with absorption and formation 
occurring simultaneously — at rates about equal to half of the heart muscle mass per 
week. The myocardium is continuously reconstituting itself by processes that are guided 
by physiologic demand and the mechanical environment in which the heart must 
function.  
 
It is hypothesized that with passive constraint and systematic reduction of an enlarging 
diseased heart, natural growth and remodeling processes can be directed such that they 
are restorative and thereby therapeutic intervention is rehabilitative. Active assist 
capabilities will ensure clinical cardiac performance metrics (e.g. cardiac output, ejection 
fraction, stroke work, etc.) are not compromised during the treatment regimen. Note that 
non-adjustable passive CSDs are designed to resist chronic dilation of end-diastolic 
volume, as well as reduce ventricular wall stress and myocardial stretch. In best case 
scenarios, passive CSDs may induce reverse remodeling toward normal size and 
function. The limiting factor in this process is the relative geometry of the device as 
compared to the diseased myocardium. Reverse remodeling events occur in response to 
the variations in the mechanical environment imposed by the device. Remodeling is an 
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adaptive behavior, and once equilibrium with the device imposed mechanical conditions 
is achieved restorative remodeling will wane. Consequently, in order to achieve full 
rehabilitation of the myocardium it is important to be able to intervene in the remodeling 
process via an adjustable device wherein the mechanical conditions required to sustain 
restorative remodeling can be maintained until normal size, shape, and function are 
achieved by natural growth and remodeling processes. A recent report [98] shows 
promise for such therapy in an ovine model. 
 
Regenerative therapies incorporating stem cells or more sophisticated engineered tissue 
constructs have demonstrated potential but have yet to be fully developed. Benefits 
observed in stem cell studies have been controversial, e.g. there is a general lack of 
evidence that implanted stem cells are actually integrating with the native tissue as 
functional cardiomyocytes [100-103]. Stem cells are typically transplanted into the 
diseased myocardium where fiber alignment is highly disorganized and disrupted by 
fibrotic tissue. In the dyskinetic myocardium, the mechanical and environmental cues 
required to guide alignment and migration of transplanted cells are severely 
compromised. The device described herein, provides the means to restore motion that 
may be critical to establishing the appropriate physiologic mechanical environment 
required to optimize cell and tissue transplant therapies.       
 
It is acknowledged that the primary limitation of this study is that the data are from only 
one animal. Nevertheless, we are not making conclusions about reliability, safety, or 
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efficacy; rather we are reporting that it is possible to deliver actions A1 and A2 with a 
device that also has features F1-F3. Only one successful experiment is needed to 
establish proof-of-concept, albeit multiple animal experiments with proper control 
groups are needed to assess reliability, safety, and efficacy of the mechanical therapy. 
Another limitation is that our imaging was restricted to a single 2-D long-axis view, and 
thus our assessment of curvature inversion is limited to this single image plane. This 
limitation, however, does not restrict our ability to assess feature F3 because our imaging 




The technology described herein has potential to serve as (1) a means of investigating 
the effects of the mechanical environment on cardiac physiology, and (2) a therapeutic 
device for the treatment of congestive heart failure. As an experimental apparatus it is 
versatile, incorporating adjustable passive constraint and synchronous active assist 
capabilities. These properties provide for a wide range of mechanical effects to be 
examined. As a therapeutic device, it is possible that a diseased hypertrophied heart can 
be gradually returned to normal size with restoration of function – rehabilitation. The 
principles guiding this approach involve simply creating the conditions under which 
natural growth and remodeling processes are guided in a therapeutic manner. The 
versatility of the device gives the practitioner or researcher options and allows for 
controlled, disease specific, flexible intervention. While the technology performed well 
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given the nature of the study, the value and utility is vested in the idea that mechanical 
factors are important stimuli in normal and pathologic physiology – particularly with 
tissues and organs that are essentially mechanical in nature. 
 
8.11 Additional Observations 
 
The device is triggered by the ECG signal which is obtained by probes built into the 
device. The built ECG probes give a more stable signal, as movement of the animal does 
not affect the signal in the way it can affect signals obtained by probes placed on the 
skin. Though triggering worked very well the device in its’ present incarnation is 
vacuum limited, i.e. vacuum fluid (gas) transport is relatively slow. Thus, the system is 
very sensitive to gate times and may be unusable at higher heart rates. In this study heart 
the heart rate varied from 68 to 78 beats per minute. The device functioned well at these 
frequencies. One notable device failure is analyzed below and is representative of the 
known potential problems with this system. In this case, tachycardia caused the pressure 
gate to open before the device was completely depressurized (Figure 12). The problem 
was resolved by momentarily shutting down the system (and extending the vacuum gate 
time). Though this was a relatively simple solution, it required (1) manual adjustment 
and thus, (2) that the device performance be monitored continuously. One potential 
software solution would be to disable the pressure gate until the device pressure falls 
below an established threshold – in essence, this may involve the device being disabled 




Another interesting observation concerned the modes by which stroke work was 
increased when the device was activated. In all cases the activation of the device resulted 
in an increase in the maximum ventricular pressure which contributed partially to 
increased stroke work. Ventricular volume is the other factor that may provide for 
increased stroke work. Note that, in the healthy heart increases in stroke work were 
associated with a decrease in the minimum volume, i.e. greater ejection. However, when 
the pre-load was reduced, increased stroke work was associated with an increase in 
maximum volume, i.e. greater filling. When contractility is reduced, increased stroke 






FIGURE 12: Tachycardia Induced Device Anomaly. Tachycardia 
coupled with slow vacuum performance caused the device to over 
pressurize. The vacuum limited nature of the system is evident in the 
distinct differences in the rise and fall times of the device pressure 
waveform. Software modification will prevent this type of failure from 
occurring by disabling the pressure gate when the device pressure is 
above a prescribed threshold. 
  
Tachycardia Induced Device Anomaly
ECG
Tachycardia Event Normal rhythm resumes
Device fails to fully de-pressurize
However, the normal rhythm is sufficient
for  full de-pressurization on subsequent cycles
Manual Shut Down
Manual Resume
Device fails to fully de-pressurize
Arrhythmia causes premature 







FIGURE 13: Modes of Increasing Stroke Work. (Top Left) Assist results in 
increased SW predominantly via increased Pmax and descreased Vmin. (Top 
Right) Assist results in increased SW predominantly via increased Pmax and 
increased Vmax. (Bottom) Assist results in increased SW via increased Pmax, as 
well as, increased Vmax and decreased Vmin. 
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9. DEVELOPMENT OF A MINIMALLY INVASIVE DEVICE CAPABLE OF 
SIMULTANEOUS ADJUSTABLE CARDIAC SUPPORT AND ACTIVE 
SYNCHRONOUS ASSIST 
 
9.1 Device Actions and Features 
 
The device described herein represents a substantial advancement over that described in 
section 8 above.  The ultimate goal remains the development of a novel device and 
therapy targeting cardiac rehabilitation through physical therapy, facilitated via artful 
management of the local mechanical environment. The major advancements achieved in 
this design iteration are (1) device deployment via minimally invasive procedures and 
(2) capability to provide simultaneous support and assist. The following two modes of 
operation or device mediated actions were sought and assessed in an acute ovine study. 
These modes of operation may be implemented independently or simultaneously. They 
are as follows:  
A1) adjustable cardiac support or passive constraint to reduce heart size  
A2) synchronous active assist to increase heart motion or stroke volume, stroke 
work, ejection fraction, and/or cardiac output  
Moreover, to enable our research goals of testing the effectiveness of the above actions 
to reverse-remodel the heart, we sought and assessed the following four inactions or 
device features:  
F1) delivered and deployed via minimally invasive surgical procedures 
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F2) does not impede heart function when it is inactive 
F3) does not invert heart curvature (nor induce similar, abnormal motions) when it is 
activated 
F4) does not dislodge, extrude or expel the heart when it is activated 
These features are necessary for chronic experiments to assess heart remodeling—i.e., 
the next phase of studies. 
 
The device and deployment system are designed for less invasive implantation through a 
1-2” sub-xiphoid incision in sheep (mini left thoracotomy in humans). The device is 
non-blood contacting, resides in the pericardial space and provides assist and support 
through direct cardiac contact or compression. Cardiac support capabilities are designed 
to be progressively actuated over a period of months, whereas assist capabilities are 
designed to temporarily restore cardiac output in the event of cardiogenic shock. 
 
There is a recent report of a device capable of adjustable cardiac support [98], and there 
are reports of a direct cardiac compression device [99] for providing synchronous active 
assist. Nevertheless, we could not find any implantable devices that provide actions A1-
A2, either independently or simultaneously, and hence, we developed the device of this 
study. To our knowledge, this report is the first for a combination device that is delivered 
via minimally invasive procedures and can perform both actions A1 and A2 




9.2 Device Construction 
 
The device was designed with an inner passive layer containing six chambers and an 
outer active layer containing six chambers. The chambers were composed of a thin nylon 
film. Each chamber had an identical helical orientation, but shifted 60 degrees so to form 
a complete circumference and form a cup-shaped structure. The inner and outer layers 
were offset such that the seams between the chambers did not overlap. Polyurethane 
tubing (0.25” d) was employed as the conduit for fluid transport to and from the 
chambers. The end of the tubing within the bladders was spiral cut to prevent the nylon 
film from collapsing onto to the tube end during the diastolic phase of assist when 
vacuum was applied to remove air in the chambers. The other tube ends were coalesced 
together into one driveline (0.375” d). Although separate in construction, tubing 
connections made the six-chambers of a given (inner passive or outer active) layer 
contiguous with the same pressure source (Figure 14). The device pressure was 
monitored continuously via use of a Millar pressure catheter transducer (Millar 
Instruments Inc., Houston, TX) placed within one of the inner passive chambers. The 
chambers were also attached to a nitinol scaffold which provided structural stability and 
served as a reference electrode for acquisition of the ECG signal used to trigger the 
device. The sense electrode was sewn to the heart apex. This epicardial electrode 
configuration provided an on-axis, robust ECG signal with a maximally polarized QRS 
complex. The ECG was routed to a BNC-2110 connector block which in turn was 





FIGURE 14: Minimally Invasive Simultaneous Function Device. A 
prototype of the minimally invasive device capable of simultaneous 
passive support and active assist,  deployed about an excised ovine heart 
that is preserved and wrapped in thin latex for handling. 
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A modified version of the custom LabView (National Instruments Corporation, Austin 
TX) program described in section 7.2 was used to monitor device pressure, acquire the 
ECG, and trigger the device (Figure 15). The primary modification incorporated a safety 
algorithm designed to prevent the device from over-pressurization, e.g. in the event of 
tachycardia. Briefly, a threshold is set for the device pressure. If the pressure is not 
below the threshold the device is not triggered and the vacuum is continued until 
sufficient fluid is removed from the device. This prevents fluid from accumulating in the 
device such that pressure continues to rise or remains abnormally high during diastole 
thereby inhibiting ventricular filling. 
 
The pneumatic system was also modified following the previous study (Figure 16). A 
network of capacitors was added to provide more flexibility in the manner in which fluid 
(air) could be transported into the device. This provides an additional safety measure as 
the device is no longer directly exposed to the high pressure source, as in the previous 
design. The capacitor network allows for variable capacitance. The pressure in the 













FIGURE 15: Schematic of the Modified LabView Application. The 
specific modifications included the use of device pressure to disable 
triggering to prevent device over-pressurization and the implementation 











FIGURE 16. Schematic of the Modified Pneumatic System. Note the 
addition of the capacitor network. This network allowed more control 
over the manner in which fluid (air) was transported into the device and 





10. ASSESSMENT OF A MINIMALLY INVASIVE DEVICE CAPABLE OF 
SIMULTANEOUS ADJUSTABLE CARDIAC SUPPORT AND ACTIVE 
SYNCHRONOUS ASSIST IN AN ACUTE HEART FAILURE MODEL 
 
10.1 Delivery and Assessment of Action A1 
 
Changes in the filling pressure of the left ventricle, known as preload, move the end-
diastolic point, the lower right-hand corner of the PV loop. These points can often be 
approximated in a linear fashion and are collectively known as the end-diastolic 
pressure-volume relationship (EDPVR), which represents the passive filling mechanics 
of the left ventricle. Adjustable cardiac support or passive constraint was accomplished 
by filling the passive chambers of the device with a fixed volume of saline. Although we 
applied a fixed volume, this action is termed adjustable cardiac support because the 
volume of fluid or amount of support can be adjusted post-implantation. We tested two 
separate cases: 1) 0mL saline, and 2) 40mL saline. With caval occlusion using a balloon 
catheter, the EDPVR for both of the above states was determined and then compared to 
assess the effectiveness of action A1 to shift the EDPVR upward or leftward (i.e., toward 







10.2 Delivery and Assessment of Action A2 
 
Synchronous active assist was accomplished by oscillating the driving pressure of the 
device in synchrony with heart contraction. With the modified pneumatic system, during 
diastole valves were opened to expose the device to the vacuum source, and the 
capacitor network to the pressure source. During systole the pressure and vacuum source 
valves were closed and the capacitor valve was opened to fill the device. The appropriate 
gate times were correlated with the QT interval.  Device pressure was varied by 
adjusting the capacitor network and pressure source. To assess the ability of the device 
to provide synchronous cardiac assist for a failing heart, we applied 0 and 20 mmHg of 
systolic assist for two cardiac states: 1) normal or baseline contractility, and 2) low 
contractility or esmolol induced, acute heart failure. For the normal cardiac state an 
active assist of 20mmHg was applied for approximately 5-10 cardiac cycles, after which 
the active assist was shut off for approximately 5-10 cardiac cycles. The same procedure 
was used for the esmolol induced failure state, first with an active assist of 20mmHg. PV 
loop analysis was used to assess cardiac function during the varying amounts of assist. 
 
10.3 Design and Assessment of F1 
 
Implantation is designed to be accomplished by using guide wires attached to a 
deployment tube containing the device, seen in Figure 17 (Top). Fixed suture loops are 
sewn to the base of the device. The guide wires are then passed through the suture loops 
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and the device is preloaded into the deployment tube. Once the guide wires are properly 
placed inside the pericardial space, the device can be pushed out of the deployment tube 
following the guide wires into the correct position. In order to get the guide wires placed 
properly, the tip of each wire is sutured together to form a scoop or spoon shape, seen in 
Figure 17 (Bottom). The scoop is inserted into the pericardial opening at which time the 
suture holding the nitinol guide wires together is released allowing them to recoil into 
the correct position. 
 
10.4 Design and Assessment of F2  
 
The device was made of thin nylon film bladders and nitinol wires that formed an open 
frame so that it was collapsible when depressurized. The design constraint of 
collapsibility when depressurized was sought so that the device itself did not impede 
cardiac function. To assess this feature, PV loop analysis was done prior to implantation 
(prior to opening the chest) and after implantation (after chest closed). Cardiac function 










FIGURE 17: Delivery and Deployment Device. (Top) Picture of guide 
wires attached to deployment tube. (Bottom) Picture of guide wires 






10.5 Design and Assessment of F3  
 
The outer half of the device chambers formed a continuous, inextensible outer shell of 
nylon whereas the inner half was in direct contact with the heart surface rather than fully 
distended. Consequently, the device was designed to apply uniform pressure to the entire 
epicardial heart surface, as uniform pressure was likely to preserve cardiac curvature—
i.e., it was unlikely to invert the ventricular wall or cause similar aberrant motions. To 
assess the heart shape during device activation, the heart silhouette was observed in 
fluoroscopy videos taken during maximal device activation. The air-heart interface was 
easily identified with x-ray imaging. 
 
10.6 Design and Assessment of F4  
 
The chambers of the device were tapered with minimal space near the apex and maximal 
space near the base. Consequently, when the device was activated it took on a cup-like 
shape as opposed to a ball-like shape—the latter being the expected shape for an inflated 
object that does not have chamber partitions. The advantage of a cup-like activated 
shape is that the heart is likely to be retained in the device rather than expelled from the 
device. This is so because there is no free air in the chest to fill the space between an 
expelled heart and the cup cavity. Rather, the heart and device were expected to be 
pneumatically coupled and coaxially fixed without the need of suturing to the heart. To 
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assess this feature, the motion of the heart silhouette relative to the wire frame on the 
device was observed in fluoroscopy videos.   
 
10.7 Surgical Procedure 
 
The care and use of the sheep in this acute implant study and terminal procedure was 
conducted at the Texas A&M University College of Veterinary Medicine in accordance 
with an active animal use protocol approved by the Institutional Animal Care and Use 
Committee of the Texas A&M University System. The adult sheep, which weighed 
approximately 70 kg, was premedicated with an anti-anxiety drug (Xylazine 0.075 
mg/lb) and an anticholinergic (Glycopyrrolate 0.01 mg/kg).  Both drugs were given 
intramuscularly.  After sedation a 16 g catheter was placed in the left jugular vein and 
anesthesia was induced with Ketamine (4.4 mg/kg) and Diazepam (0.11 mg/g) mixed 
together and given intravenously (IV) to effect. After induction, the animal was placed 
sternal and an endotracheal tube of appropriate size was placed and the animal connected 
to the anesthesia machine. Anesthesia was maintained with isoflurane gas at a 
concentration of 2-4% throughout the procedure.  The animal was clipped and prepped 
for surgery, 16g jugular catheter was replaced with an 8 French quad-lumen catheter to 
allow multiple IV access, and an orogastric tube was placed to prevent bloating.  An 
arterial catheter was placed in the left dorsal pedal artery to allow for direct blood 
pressure monitoring.  The animal was placed in dorsal recumbuncy for the remainder of 
the study.  Supporative IV fluids and mechanical ventilation were started.  Using a 
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Power Lab physiological monitoring unit; heart rate, blood pressure, central venous 
pressure, oxygen saturation, ECG, and respirations were monitored throughout the 
procedure.  A lidocaine CRI was started to prevent arrhythmias and Buprenorphine 
(0.02-0.05 mg/kg) was administered for pain. A Millar PV Catheter was placed through 
a left carotid artery cut-down and positioned by use of fluoroscopy. This conductance 
catheter was calibrated by injecting hypertonic saline into the left ventricle.  To 
determine the parallel conductance contribution of the ventricle wall, the total 
conductance with the hypertonic saline is plotted versus the conductance of blood. The 
intersection of these plots represents the parallel conductance. After placement of the 
catheter, a sub-xiphoid incision was made, and extended up the sternum to increase 
exposure for device implantation. Implantation was accomplished by direct insertion of 
the device into the pericardial sac using the guide wires and deployment tube as 














Data was acquired and processed as described in section 8.7 above. 
 
Action A1: Adjustable Cardiac Support or Passive Constraint to Reduce Heart Size  
 
The vena cava occlusion was first done with the passive support chambers filled with 
0mL of saline to establish a baseline EDPVR (Note: In the previous study, described in 
section 8, air was used in the passive chamber). After the heart recovered, the vena cava 
was occluded again but this time the passive component of the CSD was filled with 40 
mL of saline. The end-diastolic points for each PV loop are plotted in the bottom of 
Figure 18. The plots of the EDPVR for the 0mL versus the 40mL show that the EDPVR 
shifted leftward. This shift in the EDPVR indicates a decrease in the size of the left 
ventricle relative to filling pressure, i.e. the ventricle maintains the same filling pressure 







FIGURE 18:  Shifting EDPVR Revisited. (Top Left) PV loops of the 
left ventricle during vena cava occlusion in the absence of passive 
support, i.e. cardiac support of 0.0 ml. (Top Right) PV loops of the left 
ventricle during vena cava occlusion with 40mL of passive support. 




Action A2: Synchronous Active Assist to Increase Heart Motion or Stroke Volume, 
Stroke Work, Ejection Fraction, and/or Cardiac Output  
 
For the normal cardiac and the esmolol induced failure states, an active assist of 
20mmHg was applied for approximately 5-10 cardiac cycles, after which the active 
assist was shut off for approximately 5-10 cardiac cycles. A comparison of the pressure-
volume loops for both cases are in Figure 19. Notice that the PV loops for both states 
have a larger area with the active assist of 20mmHg. The area within the PV loop is 
stroke work, and it increased dramatically in the esmolol induced failure state. Figure 20 
shows two critical measurements of cardiac performance for the normal cardiac state and 
esmolol induced heart failure state. For the normal cardiac state, an active assist of 
20mmHg increased SV, EF, CO, and SW by 11.9%, 17.7%, 11.7%, and 20.5% 
respectively. For the esmolol induced heart failure state, high doses of esmolol infusion 
reduced SV by 30.7%, EF by 27.0%, CO by 29.3%, and SW by 49.9%. When the active 
assist of 20mmHg was applied to the esmolol induced heart failure state SV, EF, CO, 






FIGURE 19: Assisting the Healthy Heart and Esmolol Failure Model. 
(Left) PV loops of left ventricle for the normal cardiac state with 
20mmHg active assist transitioned to 0mmHg active assist. (Right) PV 
loops of the left ventricle for the esmolol induced failure state with 









FIGURE 20:  CO and SW in Healthy and Esmolol Models with 
Assist. Comparison of the cardiac output and stroke work for the normal 
cardiac state and esmolol induced failure state with and without assist. 
Notice the significant improvement in CO and doubling of SW for the 




Simultaneous Application of Actions A1 and A2 
 
Fluoroscopic imaging was used to assess the simultaneous application of actions A1 and 
A2. Radio-opaque die was injected into the passive chambers. The working fluid in the 
active chambers is air which is easily discernible via fluoroscopy (Figure 21). 
 
Feature F1: Delivery and Deployment via Minimally Invasive Surgical Procedures 
 
The positioning of the guide wires was checked using fluoroscopy—the lateral 
boundaries of the heart are easily discernable, and a catheter in the coronary sinus 
indicates the lower boundary of the AV groove. With the guide wires positioned 
correctly the device was deployed out of the tube and along the guide wires. Once the 
device was fully deployed, the deployment tube and guide wires were removed from the 
pericardial space and the device implantation was complete. An image, using 





FIGURE 21: Fluoroscopic Imaging of the Simultaneous Function 
Device in Action. (Top) The passive chambers are filled with contrast-
saline solution for imaging. The active chambers fully deflated. (Bottom) 
Fluoroscopic image of the fully deployed device with the active chambers 
partly inflated. 






Feature F2: Device Does Not Impede Heart Function When Inactive 
 
The PV loops acquired pre- and post- deployment are shown in (Fig 22). Stroke Volume 
(SV), Ejection Fraction (EF), Cardiac Output (CO), and Stroke Work (SW) were 
statistically similar. The heart rate increased by approximately 10% after device 
implantation; however, the heart rate was still well within the normal range. Figure 22 
also provides a comparison of Cardiac Output (CO) and Stroke Work (SW) pre and post 
device deployment. Differences were not statistically significant.  
 
F3: Device Does Not Invert Heart Curvature When Activated 
 
Inspection of images obtained via fluoroscopy demonstrates that the device does not 
invert the curvature of the heart when activated. Images were acquired continuously at a 
rate of 15 frames per second over several cardiac cycles. Figure 21 displays fluoroscopic 
images acquired during end-diastole (ED) and end-systole (ES). During systole the 
device is maximally loaded with air that is easily discernible in the images; and 
consequently, the free wall is also apparent. Although the size is reduced from ED to ES, 
the heart shape remained the same in the images—i.e., there is no evidence of curvature 








FIGURE 22: Simultaneous Function Device Pre- and Post- 
Deployment. (Top Left) and after device implantation (Top Right). 
Scales are the same, notice no significant change in the PV loops. 
(Bottom) Cardiac output (CO) and stroke work (SW), before and after 
deployment. Differences were not statistically significant. Error bars 




F4: Device Does Not Dislodge, Extrude or Expel the Heart When Activated 
 
The device takes on a rigid cup like shape (i.e., structurally supported cavity) when it is 
pressurized, and this naturally draws the heart into the device—such that suturing to the 
heart is not required. After air in the mediastinum is removed, the heart and device are 
pneumatically locked in a co-axial configuration. This feature was proven by 
fluoroscopy of device assist when actively pressurized during systole. The air filled 
bladders are easily visible on flouro, and it is evident that the heart is not displaced by 
device activation, rather the heart diameter decreases when bladders inflate (Figure 21). 
 
Cardiac De-compression via Active Assist 
 
The application of assist results in an immediate increase in stroke volume with 
concomitant decrease in both end-diastolic and end-systolic volumes, to new “assisted” 
equilibrium states.  The upper tracing in Figure 23 is the volume channel from the PV 
catheter. The lower tracing is the device pressure. Note that the device pressure goes 
from 0mmHg during systole (before assist starts) to 20mmHg during systole after assist 
begins. The end-diastolic pressure in the device is constant at 15mmHg before assist 
begins and falls to 10mmHg after assist starts. The end diastolic pressure (EDP) is high 
in this case because of passive constraint; and the result here is that the active assist 
decompresses the LV, subsequently decreases EDP, and brings EDP back into the 








FIGURE 23: LV Volume vs. Device Pressure. This illustrates the 
transition from no assist to 20mmHg of assist. The upper tracing is the 
volume channel from the PV catheter. The lower tracing is the device 
pressure. Note that the device pressure goes from 0mmHg during systole 
(before assist starts) to 20mmHg during systole after assist begins. The 
end-diastolic pressure in the device is constant at 15mmHg before assist 




Rose et al., 2001, examined the Randomized Evaluation of Mechanical Assistance for 
the Treatment, or "REMATCH” trial [72]. This was a major, multi-center (20), large 
trial (129 patients) designed to compare long-term cardiac assist treatments to 
pharmacological treatment in the areas of survival, serious adverse events, number of 
days of hospitalization and quality of life. The REMATCH trial states, "Patients with 
mild-to-moderate heart failure [73] and, recently, some with more severe disease [74] 
have been shown to benefit from drug therapy. Nevertheless, the survival and the quality 
of life of patients with severe heart failure remain limited. Cardiac transplantation is the 
only treatment that provides substantial individual benefit, but with fewer than 3,000 
donor hearts available worldwide per year, its impact is epidemiologically trivial [75]." 
To mitigate the disparity between the number of available donor hearts and the number 
of patients in need of a heart transplant (estimated at 300,000) [76], the transplant 
waiting list has stringent guidelines. Consequently, most patients who are in need of a 
transplant are not qualified to be placed on the waiting list. Thus, there is great need for 
treatment options that can restore function to failing hearts. The REMATCH trial 
contributed to the recent action of the FDA to approve cardiac assist devices for use in 
end-stage heart failure patients who are not waiting for a transplant. Prior to this, cardiac 
assist devices were only approved as a bridge to transplantation. To our knowledge, none 
of the existing mechanical assist therapies are actually designed to treat pathologic 




The progression of CHF is typically initiated by some “index” cardiac event, e.g. acute 
myocardial infarction (AMI) due to obstruction of a coronary artery. Following an initial 
recovery period from AMI, there is symptomatic deterioration and evidence of 
progressive LV remodeling characterized globally by changes in LV chamber size and 
shape, and an ongoing loss of cardiomyocytes, myocyte hypertrophy and interstitial 
fibrosis [5]. Though pharmacotherapy can slow the progression of disease, ultimately the 
therapeutic options become limited to those that include or provide some form of 
mechanical assistance. Alternatively, though the mechanics can be neglected in the early 
stages of disease without immediate adverse clinical consequences, inevitably 
mechanical implications must be reconciled. It is well understood that the heart is a 
mechanical organ and therefore as it fails, there is a loss of mechanical performance that 
must be compensated by mechanical devices, i.e. the requisite mechanical work required 
to sustain life must be performed. It is also well understood that cardiac cells and tissues 
are mechanotransducers that rely on mechanical cues to perform their respective 
integrated roles. Abberant mechanical cues stimulate cell and tissue responses that are 
pathologic. To our knowledge existing device based therapies are designed to 
compensate for the loss of cardiac work, and essentially target symptoms of disease. 
This is critical to sustain life, however a strategy wherein device based interventions 
target the aberrant mechanical environment could provide a means for recovery and 




Many mechanical assist therapies (i.e., drugs, biventricular pacing, blood contacting 
assist devices, surgical manipulations, or passive stents and constraints etc.) off-load the 
heart and thus only modulate the strain pattern indirectly (e.g., through greater ejection 
fraction). DCCD are used to improve ejection of blood from the left ventricle, and thus, 
effectively offload the heart rather than directly modulate the strain pattern, e.g., the 
rigid cup shaped device of MyoVad (a.k.a. Myotech CSS - Biophan Technologies, Inc., 
Pittsford, NY). A major disadvantage of this type of device is that the process performed 
to eject blood inverts the curvature of the heart, which induces aberrant motion and 
hence an aberrant strain pattern. The inverted curvature leads to a flawed ventricular 
wall contour and results in regions of stress concentrations in the ventricle, which might 
lead to aneurysm formation, fibrosis, and impairment of the contractility and compliance 
of the ventricle. The resulting irregular contour of the endocardial surface of the left 
ventricle may lead to localized hemostasis or turbulence, which may in turn lead to 
thrombus formation and possible thromboembolism. 
 
Curvature inversion can greatly increase ejection fraction.  However, the curvature of the 
ventricles in a normal heart does not invert during systole, thus rendering such motions 
grossly abnormal. A healthy heart, moreover, will resist having its curvature inverted 
and Artrip et al. [104] shows that heart function needs to decline by 30% before the 
effect of “non-uniform direct cardiac compression” becomes noticeable. In short, the 
heart resists assist when a DCCD induces aberrant strains.  The Vineberg device inverts 
curvature in long axis planes and short axis planes.  The Anstadt cup [105] and Cardio-
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Support System (Cardio Technologies Inc., Pine Brook, NJ) invert curvature in long axis 
planes yet preserve curvature in the short axis planes. The attachment is via vacuum on 
the apical end and the assist is via inflation of a membrane that lies between a rigid shell 
and the epicardial surfaces of the right ventricle (RV) and left ventricle (LV) (Williams 
and Artrip, 2001). The AbioBooster, [106] by Abiomed Inc. (Danvers, MA) and the 
devices of Parravicini [107] are sewn to the interventricular sulci; elastic sacks between 
the shell and the epicardial surface are inflated during systole. The DCC Patch, Heart 
Assist Tech Pty Ltd (NSW, Australia), and Parravicini devices pull on the 
interventricular sulci and push on the freewall such that the curvature will increase at the 
sulci and decrease on the freewalls.  The Heart Booster [108] is composed of 
longitudinal tubes that have elliptical cross-sections with the major axis of the ellipse in 
the hoop direction and inverts curvature in short axis planes, yet preserves curvature in 
the long axis planes. Because they were not designed to eliminate aberrant motions, it 
should not be surprising that these existing DCCDs induce aberrant strain patterns. 
Given that strain is a primary stimulus of myocardial growth and remodeling, there is a 
need for a DCCD that eliminates dyskinetic or hypokinetic motions in the heart.  
 
It is important to note that contraction strain depends on both the end-diastolic 
configuration (reference configuration) and the end-systolic configuration (current 
configuration).  The strain field is a function of the gradient (with respect to reference 
position) of the mapping of material points from the reference configuration to the 
current configuration.  The fact that a direct cardiac compression device fits the diastolic 
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configuration is inconsequential to achieving an appropriate contraction strain pattern 
because the end-systolic configuration is grossly aberrant.  For example, passive direct 
compression cardiac devices (e.g., HeartNet and CorCap) are made of biocompatible 
mesh or nitinol and placed around the heart as an elastic, compressive reinforcement on 
the left ventricle to reduce deleterious wall tension during diastole (i.e., restrict end 
diastolic volume) and to resist shape change of the ventricle during the mechanical 
cardiac cycle. It is also important to note that these devices are not adjustable in vivo, 
fibrose to the myocardium, and therefore represent a one-shot approach to therapy. 
 
To achieve a minimally invasive device, a soft-shelled DCCD has been constructed with 
inflatable, longitudinally oriented chambers that when deflated are collapsible. The 
device does not hinder cardiac performance when the device is deflated or deactivated.  
In addition, the deflated chambers are shaped and adjoined to form a structure that 
allows typical diastolic configurations.  When pressurized the chambers push on the 
exterior of the heart in such a way as to induce a systolic configuration with normal 
curvatures.  There is no need to attach the present invention to the heart because the 
heart is naturally drawn into the pressurized or activated device. Specifically, for the 
heart to leave the device (i.e., be extruded from the DCCD), the device curvature would 
need to invert, yet the device rigidity (when pressurized) resists curvature inversion.  
This is very useful because implantation time and complications due to attachment are 
minimized when this feature is present—i.e., when the activated shape of the device 
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cavity (i.e., the inner wall of the DCCD which touches the epicardial or outer boundary 
of the heart) is nearly end-systolic shape.    
 
Two problems related to the inability of previous cardiac assist devices to promote 
cardiac regeneration and reverse the effects of congestive heart failure include 1) 
Previous cardiac assist devices being studied do not provide a physiological mechanical 
environment to the damaged tissue. 2) There may be an inability for resident cardiac 
stem cells to contribute significantly to the repair of cardiomyocytes. In fact, mechanical 
signals provide important cues that regulate stem cell behavior [43]. Establishing a 
normal mechanical environment may also be critical to the ultimate success of stem cell 
transplant therapies. Cardiac muscle fiber alignment can be highly disorganized in the 
failing heart and disrupted by fibrosis. Moreover, the afflicted region is highly dyskinetic 
exhibiting abnormal motion and mechanics. Transplantation of progenitors in the 
absence of cues to drive alignment with native heart tissue may not improve global heart 
function. Therapies based on the direct introduction of cardiomyocytes into the failing 
heart assume transplanted cells will align, differentiate, and functionally integrate into 
the host tissue in the absence of the cues that normally drive these processes [62]. In 
cardiogenesis, mechanics play an important role in the appropriate pathfinding, 
differentiation, and ultimate function of embryonic progenitors [42]. In disease, 
mechanics has also been shown to play an important role in morphogenesis. The 
prospect of inducing bona fide cardiac regeneration via cell cycle activation, cell 
transplantation, or stem cell mobilization is greater now than at any previous time [103].  
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One important obstacle to be overcome involves establishing the conditions, under 
which transplanted cells may integrate, differentiate and function in harmony with the 
native tissue.  
 
While there is strong evidence that cardiac support devices e.g. CorCap,  inhibit 
enlargement, evidence suggesting restorative or rehabilitative remodeling is mostly 
missing and limited to case reports of “reverse remodeling” following treatment of an 
underlying disease (e.g., valve defect or metabolic disease) or after placement of a left 
ventricular assist device in some patients awaiting transplant. Nevertheless, contractile 
proteins are in a constant state of flux, simultaneous absorption and formation at rates 
equal to approximately half of the heart muscle mass per week. Essentially, the 
myocardium is continuously reconstituting itself by processes that are guided by 
physiologic demand and the mechanical environment in which the heart must function. 
Variations in mechanical factors influence the growth and remodeling processes that are 
continuously at work within the myocardium. With use of an adjustable cardiac support 
device (ACSD) to continually shrink the heart over a period of several months (with 3-
5% reduction every 3 weeks), it is possible that heart size can be returned to normal—
regardless of the etiology. Reduction of heart size is highly significant because size and 
function are inversely in failing hearts. Restoration of normal size could alleviate failure. 
 
With the exception of the device described by Ghanta in [98], current devices are not 
adjustable and, moreover, resist adjustment because of extensive fibrosis around the 
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heart. Though the Ghanta [98] device is adjustable in vivo, it is incapable of providing 
synchronous active assist, and requires tethering via continuous suture along the AV 
groove. With a novel design, we propose a CSD that can be adjusted in-situ over a 
period of weeks to months. We hypothesize, that this ACSD will enable proactive 
intervention whereby specific mechanical conditions can be generated and employed to 
direct growth and remodeling processes that are restorative and/or rehabilitative in 
nature, and thereby provide a substantial improvement over fixed CSD therapies. In 
addition to adjustable passive support, the device described herein has an active assist 
component that can increase stroke work as needed to provide enough cardiac output to 
keep vital organs functioning. Once the diseased heart is restored to normal size, the 
device (or a fixed CSD) can be used to prevent re-enlargement of the heart.  
 
It is acknowledged that the primary limitation of this study is that the data is from only 
one animal. The purpose of this study was to establish proof-of-concept as it relates to 
device function. In addition, the purpose of this report is to provide a foundation for the 
immediate development of other device based therapies targeting pathologic mechanical 
factors, rather than merely compensating for loss of mechanical function, particularly 
when that function may be restored via physical rehabilitative therapy. Multiple animals 
experiments with proper control groups are needed to assess reliability, safety, and 
efficacy of this mechanical therapy. Another limitation is that our imaging was restricted 
to a single 2-D long-axis view, and thus our assessment of curvature inversion is limited 
to this single image plane. This limitation, however, does not restrict our ability to assess 
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feature F4 because our imaging was sufficient for visualizing the heart apex location 




The technology described herein has potential to serve as (1) a means of investigating 
the effects of the mechanical environment on cardiac physiology, and (2) a therapeutic 
device for the treatment of congestive heart failure. To our knowledge it is the first 
device capable of providing adjustable passive support and synchronous active assist – 
simultaneously. Moreover, it is collapsible and can be delivered via minimally invasive 
surgical procedures. The versatility of the device provides for a wide range of proactive 
intervention possibilities. As a therapeutic device, it is possible that a diseased 
hypertrophied heart can be gradually returned to normal size with restoration of function 
– rehabilitation. The principles guiding this approach involve simply creating the 
conditions under which natural growth and remodeling processes are guided in a 
therapeutic manner. The versatility of the device gives the practitioner or researcher 
options and allows for controlled, disease specific, flexible intervention. While the 
technology performed well given the nature of the study, the value and utility is vested 
in the idea that mechanical factors are important stimuli in normal and pathologic 





11. DEVICE LIMITATIONS AND CAPABILITIES 
 
The device described herein incorporates two basic mechanical functions, (1) load 
bearing and (2) fluid transport. The present design consists of two layers of six pressure 
chambers each. The chamber geometries of the outer active layer are necessarily 
different than those of the inner passive layer (Figure 24). To test the ability of the 
device to bear a pressure load five chambers of each design were used. The chambers 
were attached to a simple sphygmomanometer system in order to determine the 
magnitude of pressure at which the chamber fails either by burst or plastic deformation. 
Pressure was increased in increments of 10mmHg.  
 
Deformation of the nylon material begins when pressure exceeds 130mmHg in the larger 
passive chambers (Table 2). Maximum operating pressure for the device is 60mmHg. 
Thus, the nylon material is sufficient and safe with respect to pressure induced failure. 
The pressurized diameter of the outer chambers is smaller than that of the inner 
chambers. Thus, at similar pressures, according to the Law of Laplace, the stresses in the 
nylon are lower in the outer chambers than in the inner chamber counterparts. 
Accordingly, the outer chambers tended to fail at the seams rather than by plastic 
deformation of the nylon (Table 3). Failure of the seams occurred at similar pressures 
and is not a concern given the operating pressure of the device. All panels are tested for 







FIGURE 24: Active and Passive Device Chambers. Left – The larger 
passive chamber design. These chambers typically failed due to plastic 
deformation of the nylon. Right – The smaller active chamber design. 
These chambers typically failed at the seams. The geometry is more 
intricate thatn the larger passive chamber design and thus, creating the 
seal was more difficult. All chambers were tested to ensure the integrity 









TABLE 2: Inner Passive Chamber Pressure Capacity Test. The nylon 
material fails when pressures exceed 130mmHg. Seams generally held up 
well, i.e. bursts at the seams are likely due to manufacturing flaws. 
 
Component                        Outcome 
PC1 Continuous Deformation at 140mmHg  
PC2 Continuous Deformation at 150mmHg 
PC3 Continuous Deformation at 140mmHg 
PC4 Burst at seam at 130mmHg, signs of deformation present 











TABLE 3: Outer Active Chamber Pressure Capacity Test. Slow leaks 
are suggestive of the difficulty in sealing the seams with this geometry. 
Deformation of the nylon material occurred at higher pressures as 
compared to the passive chambers, likely due to the smaller radius. 
 
Component                        Outcome 
AC1 Burst at Seam at 140mmHg  
AC2 Slow Leak, Burst at Seam at 150mmHg 
AC3 Continuous Deformation at 150mmHg 
AC4 Slow Leak at 100mmHg, Burst at Seam at 140mmHg 
AC5 Slow Leak, Burst at Seam at 160mmHg 
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In order for the device to function properly it is imperative that fluid be shuttled in to and 
out of the device efficiently and reliably. It was empirically determined that the device is 
vacuum limited; the challenge of the fluid transport problem is one of evacuating the 
fluid from the device such that the heart may fill during diastole. The QT interval is 
measured from the start of the QRS complex and the end of the T wave in the ECG. For 








Normal QTc intervals range from .3 to .45 seconds. Using this information, the 
corresponding “normal” QT intervals are plotted versus heart rate in Figure 25. Given 
the vacuum limited nature of the system the maximum QT values were used in an 
experiment designed to determine the maximum heart at which the device could operate 
reliably. A function generator was used to provide a sine wave to trigger device. The 
frequency was increased 15 cycles per minute, beginning at 60 cycles per minute. With 
each increase the device gates were adjusted according to the corresponding QT interval. 
The system was configured such that the device applied 30mmHg to a rigid mock heart 
setup. The device maintained reliable assist at simulated heart rates up to 135 BPM. At 
150 BPM, performance varied as evidenced by increasing variance in applied. At 165 
BPM, device performance was erratic (Figure 26). Thus, the assist function of the device 






FIGURE 25: Normal QT Interval versus Heart Rate. The device 
range of operation is limited by the ability to transport fluid. Specifically, 
the challenge is removing all fluid during diastole, as the heart fills. Thus, 
as a worst case scenario, the device was tested at the maximum QT for 
































FIGURE 26: Device Operational Range Results. A function generator 
was used to produce the large sine wave that was used to trigger the 
device. All values were normalized in order to fit on the same display. To 
determine the actual pressure applied to the heart model in mmHg simply 
multiply the plotted pressure value by 10. Top - At heart rates near or 
below 135 BPM the device was capable of providing 30mmHg assist 
reliably. Middle - As heart rate increased to 150BPM and QTc 
subsequently decreased, performance began to deteriorate as evidenced 
by increasing variance in applied pressure. Bottom – By 165 BPM 
performance was totally unreliable.  
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12. MANIPULATING THE MECHANICAL ENVIRONMENT TO OPTIMIZE 
STEM CELL THERAPY 
 
Stem cell therapy for the treatment of heart failure remains promising but is as yet not 
fully developed. Results of stem cell studies have collectively been inconclusive, and 
perhaps even controversial. Some crucial observations have not been reproducible and 
conclusions from similar findings have been conflicting [100-103]. Thus, though the 
concept is simple - cultivate progenitor cells outside the heart then transplant them into 
the heart and hope that they will eventually integrate into the intact myocardial tissue - 
the results have been ambiguous, marginal, or negative, suggesting that transplantation 
of progenitor cells into a failing heart will not necessarily lead to substantial clinical 
improvement [62].  
 
Mammalian cardiogenesis requires many cell types – atrial and ventricular 
cardiomyocytes, conduction system and pacemaker cells, smooth muscle cells, valvular 
cells, endothelial cells, and endocardial cells. Multipotent progenitors in the early 
embryonic field can be classified into two groups, the Primary and Secondary Heart 
Field. The absence of molecular markers for primary heart field progenitors has thus far 
rendered isolation and characterization of these progenitors impossible. However 
purified secondary progenitors, i.e. myocardial, smooth muscle and endothelial 




The present goal of stem cell therapy is cardiac regeneration. At present, this objective 
has not been met. To accomplish cardiac regeneration, generally three types of tissue 
generation are required (1) angiogenesis, (2) arteriogenesis, and (3) cardiomyogenesis. 
Given this fact, bone marrow derived cells are likely the best cell type to use in meeting 
the cardiac regeneration objective. In bone marrow one may find the endothelial 
progenitor cells (EPC), necessary for angiogenesis and arteriogenesis; and the 
mesenchymal precursor cells (MPC), necessary for arteriogenesis and cardiomyogenesis. 
Though promising, early reports have suggested implantation of this cell type is 
unreliable, e.g. at 18 hours post-delivery, only 1% of the cells remained in the heart.  
Skeletal myoblasts have been used to treat ischaemic cardiomyopathy but there have 
been problems with arrhythmias when using this cell type. While this problem decreases 
over time, the reason for this occurrence is not known. Proponents suggest that the cells 
are integrating into myocardial tissue whereas opponents propose that the cells have 
simply died. Presently, cell tracking studies are insufficient to answer this question 
definitively. Efforts have also targeted harvest and cultivation of resident cardiac stem 
cells. In this case autologous cells are obtained via biopsy and cultured ex vivo [100].   
 
Cardiac muscle fiber alignment can be highly disorganized in the failing heart and 
disrupted by fibrosis. Moreover, the afflicted region is highly dyskinetic exhibiting 
abnormal motion and mechanics. Transplantation of progenitors in the absence of cues 
to drive alignment with native heart tissue may not improve global heart function. 
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Therapies based on the direct introduction of cardiomyocytes into the failing heart 
assume transplanted cells will align, differentiate, and functionally integrate into the host 
tissue in the absence of the cues that normally drive these processes [62]. In 
cardiogenesis, mechanics play an important role in the appropriate pathfinding, 
differentiation, and ultimate function of embryonic progenitors [42]. In disease, 
mechanics has also been shown to play an important role in morphogenesis.  
 
The prospect of inducing bona fide cardiac regeneration via cell cycle activation, cell 
transplantation, or stem cell mobilization is greater now than at any previous time [103].  
One important obstacle to be overcome involves establishing the conditions under which 
transplanted cells may integrate, differentiate and function in harmony with the native 
tissue. The cues required to drive the transplanted cells through the appropriate processes 
are largely mechanical in nature. Mechanical cues are transduced by cells which respond 
biochemically, initiating a variety of potential responses, i.e. proliferation, migration, 
contraction, alignment, etc. Herein it is proposed that the promise of stem cell therapy as 
a means of treating heart failure can be realized by mediating the local mechanical 
environment. Thus, a combination therapy incorporating a device based intervention 
designed to manipulate the mechanical environment about the heart with a stem cell 
based therapy is presented as superior alternative to either approach alone.  
 
It is important to note that the “whole” of this specific combination approach will exceed 
the “sum of the parts”. Stem cell therapies, which have already demonstrated some 
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benefit, will likely show improved efficiency as important mechanical cues will now be 
present to guide stem cell processes. Device performance will also increase as the 
incorporation of healthy stem cells will accelerate the cardiac recovery and rehabilitation 
normally associated with this “physical therapy”. In combining these specific therapies, 
a synergistic response is produced as the benefits of either are maintained while 
promoting improved responses from each. Thus, it is also important to note that the 
device based intervention must be versatile, i.e. capable of producing a range of 
mechanical circumstances, enabling deliberate strategic intervention aimed at 





13. MANIPULATING THE MECHANICAL ENVIRONMENT TO OPTIMIZE 
CARDIAC TISSUE GRAFT THERAPY 
 
Similar to the proposed combination therapy with stem cells, the device described herein 
could provide a method of manipulating the cardiac mechanical environment to promote 
the integration and optimize the function of engineered tissue constructs designed for 
cardiac regenerative therapy. Following a myocardial infarction (MI), ischemia is 
prevalent characterized by damaged, dysfunctional, and/or fibrotic myocardial tissue. 
There is great interest in therapies designed to restore cardiac function and/or regenerate 
cardiac tissue. For example, various types of stem cells may be injected directly into the 
damaged region or into coronary arteries feeding the damaged region to help regenerate 
this damaged tissue into healthy cardiac tissue. There has been some success with this 
type of cardiac regeneration therapy; however, the potential success of stem cell therapy 
is limited by (1) the dyskinetic or hypokinetic motion of the damaged heart tissue – the 
ability of the cells to differentiate into functional cardiomyocytes integrated into the 
native tissue is compromised by the absence of the appropriate mechanical cues in the 
local diseased environment; and (2) for true regeneration to occur, multiple cell types 
must be delivered into the diseased region – in addition to the precursors to 
cardiomyocytes, cells capable of promoting angiogenesis, e.g. endothelial progenitor 
cells, and arteriogenesis may be required. Consequently there is increasing interest in 
developing more sophisticated engineered structures for transplant with cardiac 
regeneration as the therapeutic target. These constructs incorporate multiple cell types 
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and synthetic or biologic scaffolds to provide structural framework for the tissue graft. 
Engineering functional tissues in vitro provides advantages to current stem cell 
strategies, particularly in addressing limitation (2) described above. However, it is 
anticipated that the ability of the tissue engineered construct to integrate and function 
with the native tissue will be constrained by the local mechanical and environmental 
cues. The device described herein is capable of manipulating the mechanical 
environment such that the mechanical factors necessary for proper tissue integration and 
function can be modulated as necessary to optimize performance. 
 
As stated previously, therapies based on the direct introduction of cardiomyocytes into 
the failing heart assume transplanted cells will align, differentiate, and functionally 
integrate into the host tissue in the absence of the cues that normally drive these 
processes. It unlikely that the transplantation of cardiac muscle progenitors or their 
differentiated progeny, will lead to substantial long term clinical improvement in the 
absence of cues to drive their appropriate linear alignment with the native heart tissue 
[62]. Moreover, cardiac regeneration may require many cell types – atrial and ventricular 
cardiomyocytes, conduction system and pacemaker cells, smooth muscle cells, valvular 
cells, endothelial cells, and endocardial cells.  
 
According to a recent review by Zimmerman [109], there are two broad approaches to 
the use of stem cells in cardiovascular therapeutics – cell based therapies which entail 
the delivery of a volume or mass of cells to the tissue being targeted for treatment; and 
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tissue engineering which may involve generating sheets of tissue and ultimately whole 
organs. Several cell types are typically used as basic units to grow specific types of 
tissue. A structural framework or scaffolding is also necessary as a structural framework 
on which to build [100]. The resulting constructs may subsequently be assessed ex vivo, 
before implantation to support or replace a significant portion of a failing heart in vivo 
[110]. Tissue engineering-based myocardial repair approaches in animal models have 
been reported [111, 112]; and one year follow-up data from a human tissue engineering 
trial (MAGNUM-trial) has been published [113]. The construction of 3D synchronously 
contracting vascularized human cardiac tissue that exhibits typical structural and 
functional properties of early cardiac tissue has been reported. It is proposed that 
engineering vascularized cardiac tissue before implantation to the infarcted myocardium 
will enable improved graft survival and may result in an increased functional benefit 
[114]. Restoring or at least enhancing heart muscle function by grafting of tissue 
engineered myocardium seems foreseeable and may not only be applicable in older 
patients with heart failure but also in children with congenital defects. Ultimately, tissue 
engineering based myocardial regeneration may be an attractive alternative to heart 
transplantation and other surgical interventions to rebuild the heart [110].  
 
Zimmerman [109] identifies several tissue engineering technologies that have been 




• A classical biomaterial approach, wherein biocompatible materials are chemically 
engineered for use as growth substrate for cells. This scaffold would ideally be designed 
to offer initial structural support, but be degraded over time. Several materials have been 
used, including polylactic acid (PLA) and polyglycolic acid (PGA) and mixtures thereof 
[115, 116]. Alternatively, alginates [117], polysaccharides derived from seaweed, and 
gelatin/collagen sponges [118, 119] have been employed. 
 
• A cell entrapment approach, aiming at concentrating cells at a high density within a 
defined three-dimensional environment to facilitate spontaneous cell aggregation [120 – 
122]; Spontaneous assembly of mostly spherical cell aggregates occurs if 
cardiomyocytes are cultured at high densities in bioreactor suspension cultures [123]. 
During the naturally occurring condensation process of hydrogel/cellmixtures muscle 
aggregates fuse to form a functional syncytium. This process can be optimized by 
imposing mechanical strain onto the resulting tissue constructs [121, 122, 124]. 
Importantly, hydrogel-based engineered heart tissues (EHTs) display several structural 
and functional properties of native myocardium and can further be optimized by growth 
factor conditioning, electrical stimulation, and addition of non-myocytes to the initial 
cell mixture [122, 125]. 
 
 
• A cell sheet engineering approach, aiming at stacking cell monolayers to generate tissue 
“sandwiches” [126]; The development of culture surface coatings containing poly(N-
isopropylacrylamide), being either hydrophobic or hydrophilic depending on the 
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environmental temperature to facilitate cell attachment and detachment at high (37°C) 
and low (20°C) temperatures, respectively, has enabled the controlled release of 
monolayer cell cultures from its underlying substrate [127]. Stacking cell layers can 
eventually be utilized to generate complex three-dimensional tissue with a specific organ 
function [128]. The absence of vascularization does, however, restrict the size of 
individual cell sheet stacks to three to four layers [126]. This limitation may be 
overcome in vivo by a so called “polysurgery approach” that would, however, 
necessitate repeated access to the implantation site to sequentially stack cell sheet 
sandwiches in vivo after previous grafts have become properly vascularized [129]. In a 
modification of the original cell sheet engineering approach, spontaneous detachment of 
cell monolayers from uncoated or laminin coated culture dishes has been exploited to 
generate cardiac muscle constructs [130]. 
 
• Micro-tissue technology, being essentially a modification of the commonly used 
hanging-drop cell culture system [131]; Micro-tissues can be generated by aggregating 
cardiomyocytes in hanging-drop cultures [131, 132]. They demonstrate several features 
of a functional myocardial syncytium. 
 
 
• An organ decellularization-recellularization approach. De-cellularized hearts provide an 
underlying extracellular matrix, perfusable vascular architecture, competent acellular 
valves, and intact chamber geometry for the development of bioartificial hearts. The 
constructs are re-seeded with cardiac or endothelial cells [133]. 
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“An average myocardial infarction causes a loss of approximately 1 billion myocytes 
[134]. Subsequently, scar tissue forms and the remaining myocardium responds to the 
loss of contractile tissue by cardiomyocyte hypertrophy. The latter may transiently 
suffice to compensate for the loss in myocardial performance but will in the long-run 
perpetuate the myocardial damage, eventually leading to heart failure. If a defined defect 
can be clearly localized after a myocardial insult, engineered heart muscle may be placed 
on top of it, to locally support the failing heart and inhibit further deterioration…In an 
alternative approach, localized defects (e.g. aneurysms and transmural scars) may be 
surgically excised, using for example a Dor-procedure [135], and replaced with 
tissueengineered myocardium [136, 137]. This approach is expected to be superior to an 
epicardial application of tissue engineered myocardium, because it avoids potentially 
interfering effects of otherwise underlying non-contracting scar tissue. It may, however, 
especially if applied in the left ventricle, be complicated by (1) high systolic left 
ventricular pressures (requiring bioartificial grafts with high burst strength), (2) 
thrombus formation (requiring non-adhesive/non-thrombogenic tissue surfaces), and (3) 
arrhythmias (requiring seamlessly integrated and physiologically conducting grafts 
bridging the transmural defect)” [109].  
 
The device described herein would provide a means to control the mechanical 
environment, providing support, constraint, and active assist. All of which would 
improve the likelihood of success particularly in procedures wherein the transmural scars 
are excised and replaced with tissue-engineered myocardium. Potential complications 
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associated with high left-ventricular pressures would likely be avoided altogether, and 
complications related to arrhythmias would likely be reduced as active assist could 







14. MANIPULATING THE MECHANICAL ENVIRONMENT TO MAINTAIN 
ORGAN VIABILITY FOR TRANSPLANT 
 
For patients with end stage heart failure, heart transplant is the preeminent choice of 
treatment. Over the last decade, the incidence of end stage heart failure has been 
increasing due to the rising age of the population and survival rate of individuals 
experiencing myocardial infarction. Currently there are over 2,700 patients on the heart 
transplant waiting list (OPTN – Organ Procurement and Transplantation Network – as of 
Feb 2009) and many more patients that do not currently qualify for heart transplant but 
could benefit if more donor hearts were available. Progress has been made in the 
availability of donor hearts; however progress in the sustainability of those hearts has 
been lacking. The current four hour time frame for the viability of donor hearts is a 
major shortcoming, not only limiting the time necessary for the preparation of transplant 
surgery but also limiting the geographic location from which donor hearts can be 
transported.  
 
Current methods of transporting and preserving hearts for transplant once the heart is 
removed include: flushing the heart clean of blood, placing the heart in a bag of storage 
solution, and packing the heart in an insulated container of ice. Using the current method 
of preservation and transportation, the donor hearts must be implanted within 6 hours of 
the donor’s death (one hour for the procurement of the heart, four hours for transport, 
and one hour for transplant surgery) or the heart will no longer be viable. This process 
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attempts to slow the cell death and does little to sustain organ health. The time constraint 
often requires the presence of costly around-the-clock transplantation teams able to 
quickly utilize incoming donor hearts 
 
There had been a long held belief that subjecting a harvested heart to low temperatures 
substantially lowers metabolic rates to negligible levels, thus depriving the heart of 
oxygen did not result in cellular damage. However, research has shown that subjecting a 
harvested heart to temperatures of four degrees Celsius only lowers metabolic rates up to 
ten percent [138]. Even at low metabolic rates, depriving the heart of oxygen results in 
the switch from aerobic metabolism to anaerobic metabolism further degrading tissue, as 
cardiomyocytes begin to consume themselves and release metabolic toxins. In addition 
to myocardial damage, oxygen deprivation may also cause coronary vascular endothelial 
and smooth muscle injury leading to coronary vasomotor dysfunction. 
 
The need for sustaining the viability of donor hearts has resulted in several perfusion 
systems, which perfuse the heart with various oxygenated solutions in an attempt to 
provide the heart with nutrients necessary for survival. Perfusion systems have three 
advantages over current heart preservation techniques. 1) Perfusion with oxygenated 
solutions has the ability to prevent ischemia, anaerobic metabolism, and reperfusion 
injury. 2) Perfusion allows for a more effective delivery of oxygen and nutrients to 




Many studies have shown that perfusion can substantially sustain a heart ex vivo 
compared to simple immersion [139, 140]. However, an ideal perfusate that would 
mimic physiological conditions is still up for debate. Several additives, temperatures, 
pressures, and pH levels have been examined and have been found to affect the hearts 
viability. Perfusion solution additives include albumin, potassium, calcium, magnesium, 
Lidocaine, glucose, insulin, and vasodialators. Albumin has been shown to decrease 
edema formation. Potassium and calcium, while optimal levels are unknown, are thought 
to improve viability during perfusion preservation. Magnesium protects myocardial 
mitochondria and is a cofactor in intracellular enzyme reactions. Lidocaine decreases 
ventricular fibrillation. Glucose and insulin complement each other and protect against 
myocardial injury as long as myocardial cells have sufficient oxygen and removal of 
metabolic byproducts. Vasodialators improve coronary flow during perfusion. Ideal 
perfusion temperatures have been found to be at or above 20° C, because the protective 
effects of metabolic substrates such as glucose and insulin are experienced. Ideal pH 
levels and pressures are still up for debate [139].  
 
Current perfusion systems usually have the ability to regulate oxygenation, thermal 
conditions, and may or may not include electrical stimulus. However, the mechanical 
environment is dramatically altered. The mechanical cues necessary for proper cell 
physiology are absent. Aberrant mechanical factors can lead to myocardial degradation 
and cell death. Contractile proteins are in a constant state of flux with absorption and 
formation occurring simultaneously—with rates equal to approximately half of the heart 
126 
 
muscle mass per week. Essentially, the myocardium is continuously reconstituting itself 
by processes that are guided by physiologic demand and the mechanical environment in 
which the heart must function. Variations in mechanical factors influence the growth and 
remodeling processes that are continuously at work in the myocardium. It is therefore 
essential to provide a mechanical environment that is conducive to myocardial survival. 
 
Ex vivo, the heart may not have the ability or nutrients required to perform the 
mechanical work necessary for myocardial survival. Therefore, pacing the heart alone 
will not produce the desired physiological motion needed for heart viability. Mechanical 
assist in the form of direct cardiac compression in a manner that promotes physiological 
strain patterns and motion is necessary to maintain viability.  
 
A perfusion system that can provide a near physiological environment by applying 
mechanical assist, electrical stimulation, temperature regulation, and perfusion of 
oxygenated solutions is necessary for maintaining heart viability. Increasing the time of 
heart viability will not only expand the organ donor pool but it will also allow more time 
for histological compatibility testing and overall surgical preparedness, resulting in 
fewer wasted donor hearts, organ rejection, and surgical mistakes.   
 
The device described herein could provide the means to reconstruct an in vivo 
physiological fluid and solid mechanical environment. Application of mechanical assist 
and electrical stimulation, regulation of temperature, and perfusion with a solution 
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composed of oxygen and nutrients are necessary for cardiac tissue survival and will 
provide a near physiological environment conducive to maintain viability of the 




15. SUMMARY AND CONCLUDING REMARKS 
 
The device presented herein could function well as a clinical device based therapy or a 
research tool, e.g. to investigate disease processes, and/or the effects of specific 
mechanical factors on cardiac growth and remodeling processes. The concluding 
remarks will focus on the clinical application, and in so doing should reveal the value as 
a research tool as well. Though initiated by some index cardiac event, e.g. myocardial 
infarction, and the subsequent compensatory neurohormonal mechanisms, aberrant 
growth and remodeling of the left ventricle eventually progresses independent of the 
neurohormonal status of the patient. Evidence suggests that mechanical factors are 
critical to healthy growth and remodeling of biologic tissues. As the diseased ventricle 
remodels, the local mechanical environment is altered and exhibits symptoms of disease, 
i.e. the mechanical environment itself becomes wrought with disease. Erroneous 
mechanical cues contribute to further aberrant growth and remodeling processes. A 
positive and deadly feedback loop emerges, stimulating spurious remodeling processes 
that ultimately render the vital organ incapable maintaining of homeostasis.  
 
While it is important to recover the mechanical work that can no longer be provided by 
the organ itself, it is equally important to treat the pathologic mechanical environment. 
Present device based therapies are designed exclusively to (1) provide cardiac assist or 
alternatively, recover mechanical work, or (2) mechanically inhibit further detrimental 
growth and remodeling processes.  In the each case, the focus on mechanics is myopic. 
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Recovering mechanical work with DCCDs is critical to sustain life, however, there is 
much more to consider. These devices impose a new set of mechanical stimuli and may 
do further damage to the mechanical environment, e.g. invert the curvature of the heart, 
effectively eliminating any possibility of cardiac recovery or rehabilitation. If we instead 
treat the diseased environment, i.e. restore the mechanical environment – the kinesis of 
the myocardium, in so doing we will recover the lost mechanical work and provide the 
mechanical cues necessary for growth and remodeling processes that are potentially 
restorative and rehabilitative in nature. With present CSDs, we may inhibit the 
symptoms of disease and perhaps slow the progression of disease, yet we are failing to 
provide true therapy, that is, we are failing to provide a legitimate attempt to cure the 
disease. Again, if we treat the mechanical environment, and seek to restore healthy 
mechanical cues, not only will we accomplish the goal of inhibiting disease progression, 
we may very well reverse the disease induced remodeling process and thereby reduce the 
size of the diseased ventricle. 
 
It is interesting that given the long history of rehabilitative physical therapy with 
biologic tissues and organs, that efforts to provide such therapy for the diseased 
myocardium are conspicuously absent. Hippocrates (460-370 BC) proposed the 
application of what is now known as biomechanics, to treat musculoskeletal defects and 
injuries, thousands of years ago. Thus, Hippocrates advanced the field of orthopaedics 
before it existed formally. Nicolas Andry coined the term “orthopaedics” in 1741. From 
Greek, the word ortho means “to straighten”, paedia means “children”. Thus, early 
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orthopaedics focused on treating congenital defects and scoliosis. The point here is that 
for hundreds or even thousands of years we have known that by manipulating 
mechanical factors, by altering the mechanical environment, we can guide natural 
growth and remodeling processes as a therapy.  
 
Presumably due to the long history of the field of orthopaedics, an important design 
consideration when developing a device based therapy or prosthetic, is the impact the 
device will have on the mechanical environment. It is well understood that it is not 
sufficient to merely treat the anomaly at hand, lest one create yet another problem. 
Engineers developing device based therapies for cardiovascular diseases must also 
adhere to this understanding. Vascular stents developed to treat diseased arteries by 
serving as a scaffold designed to prop open stenotic regions often cause restentosis, 
particularly near the ends of the stent – a region of substantial compliance mismatch. 
This compliance mismatch between stent and artery is not extremely difficult to 
overcome. It is curious that it was neglected in the first place, and particularly 
confounding that it remains neglected with the advent of drug-eluting stents. Rather than 
simply resolve a design flaw that imposes adverse mechanical conditions on the artery, 
we treat the consequences of the flaw with pharmaceuticals? It is acknowledged that 
some form of restenosis may occur regardless of compliance matching design 
considerations and that drug eluting stents may still be beneficial or necessary. The point 
here is to illustrate the perceived reluctance of those in the cardiovascular device 
industry to diligently and earnestly consider the mechanical implications of their 
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therapeutic solutions particularly given modern understanding of mechanobiology. In 
this case, the expense associated with device design that is thoughtful of the impact on 
the mechanical environment is not financial, rather intellectual. 
 
The physical differences in appearance and function, between the device presented 
herein and previously existing devices, are often very subtle. On the other hand, the 
philosophy behind these subtle differences is not so subtle. Existing DCCDs invert the 
curvature of the heart, inducing aberrant strain patterns. The philosophy behind these 
devices is simple – squeeze as needed to generate sufficient blood flow. There is an 
inherent disregard for the natural, healthy, physiologic mechanical environment. While 
the active component of the device presented herein is similar to existing DCCDs, and 
the passive component is similar to existing CSDs; the device as a whole is in essence 
something altogether different. It is designed first to treat the mechanical environment, 
to enable the physician to manipulate the mechanics about the heart in such a way as to 
create the conditions most favorable for natural growth and remodeling processes that 
are restorative and rehabilitative in nature. In so doing, as a “side effect” we accomplish 
the goals of existing DCCDs and CSDs. 
 
It is acknowledged that no evidence of reverse remodeling as a consequence of treatment 
with this device has been presented in this work. Pursuit of such evidence is absolutely 
essential to developing effective treatment plans and will be initiated in future studies. 
Nonetheless, we know that mechanical factors guide growth and remodeling processes 
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in the heart. Moreover, there is evidence in the literature that reverse remodeling in 
diseased hearts can be stimulated by device based therapies (see Section 3 above). These 
are often isolated instances and are likely due to specific patient conditions, i.e. for a 
given subset of patients the mechanical therapy coincidentally creates the appropriate 
conditions for reverse remodeling to occur. Alternatively, with some CSDs, e.g. Corcap, 
reverse modeling may occur but is limited; once equilibrium with the non-adjustable 
device is reached, reverse remodeling ceases.  The goal here is to provide the physician 
with a versatile tool, incorporating design features and capabilities that enable the 
generation of a broad range of mechanical stimuli and support. Thus, treatment could be 
deliberately aimed at creating conditions conducive to reverse remodeling processes. 
The physician would essentially be able to artfully provide physical therapy for the heart 
to stimulate natural growth and remodeling processes that are potentially restorative and 
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